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ABSTRACT 
 
NITRIC OXIDE RELEASE FROM POLY(LACTIC-CO-GLYCOLIC ACID) 
NANOPARTICLES AND TITANIUM ALLOY 
 
 
 
By 
Nina Allyn Reger 
August 2017 
 
Dissertation supervised by Dr. Ellen S. Gawalt  
Current methods for the treatment of bacterial infection involve the use of 
systemic antibiotics, which are high concentrations of antibiotics delivered over a long 
period time. Unfortunately, the use of systemic antibiotics can cause harmful side effects 
to the patient and increases the possibility for antibiotic resistance. The delivery of 
antibiotics or alternative antimicrobial compounds, such as nitric oxide, directly to the 
site of infection would decrease the amount of antibiotic necessary to treat a bacterial 
infection.  
Poly (lactic-co-glycolic acid)/polyvinyl alcohol nanoparticles and a titanium-
aluminum-vanadium metal oxide alloy implant were surface functionalized to deliver 
nitric oxide. Polymer nanoparticles can be used to deliver nitric oxide to patients with 
extensive bacterial infection in the lung, while the modified metallic implant can be used 
 v 
to prevent bacterial cell adhesion onto the surface post implantation. These surfaces were 
covalently modified with S-nitrosothiols, and characterized using infrared and ultraviolet-
visible spectroscopic techniques. The attachment of the S-nitrosothiol to the nanoparticle 
surface resulted in a nmole of nitric oxide per milligram of nanoparticles release under 
physiological conditions, while the modified titanium alloy released a nmole of nitric 
oxide per cubic centimeter. The low concentration of nitric oxide released from the 
nanoparticle and titanium alloy surfaces reduced Escherichia coli growth, indicating that 
S-nitrosothiol remains active against bacteria after covalent immobilization to the surface. 
The S-nitrosothiol modified titanium alloy inhibited Staphylococcus epidermidis growth, 
indicating effectiveness against a gram-positive microbe. Combining both nitric oxide 
releasing materials with tetracycline, a commonly prescribed antibiotic, increased the 
effectiveness of the antibiotic, which allows for lower doses of antibiotics to be used. 
Thus, the polymer nanoparticles and titanium alloy developed here have the capability of 
delivering an antibiotic alternative, nitric oxide, directly to the site of an infection, 
reducing the need for harmful systemic antibiotics and the possibility of antibiotic 
resistance.  
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Chapter 1. Background 
1.1 Introduction  
Each year in the United States, upwards of 2 million individuals contract 
antibiotic resistant infections. Approximately 23,000 of those affected succumb to these 
bacterial and fungal infections annually.1 The economic burden of these illnesses cost the 
United States $20 billion in additional healthcare costs.2 These infections are a result of 
inappropriate antibiotic prescribing, dosing, and ultimately overuse.3 Antibiotics are 
found in the water we drink and the food we eat, as it is often used as a dietary 
supplement for food animals to promote growth.2, 3 The continuous exposure to these 
antibiotics fuels the potential for a bacterial species to become resistant.3 Additionally, 
30-50% of the antibiotics prescribed to treat an infection are not needed (i.e. viral versus 
bacterial infection) or are not effective as prescribed (i.e. the bacterial species present).2, 3 
The current development of new classes of antibiotics is limited, and thus appropriate 
usage of current antibiotics or alternative antimicrobial compounds are required to ensure 
the long-term effective treatment for bacterial infections.4 
 
1.2 Antibiotic Resistance and Biofilms  
1.2.1 Antibiotic Resistance  
In 2010, twenty-two doses of antibiotics were prescribed per person in the United 
States.3 These systemic antibiotics are administered typically in pill form and when 
given, can cause toxic effects to cells and organs.5 This delivery method often requires 
high doses to ensure the antibiotic reaches the specific site of infection within the body.6 
For example, vancomycin is typically administered intravenously to a surgical patient 
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two hours before a procedure begins to ensure the antibiotic is present at the surgical 
site.7 Additionally, high dosages for prolonged use can contribute to antibiotic resistance, 
leading to increased treatment costs, increased risk of side effects, longer hospital stays, 
and higher mortality rates.3, 7, 8 Localized delivery of antibiotics, in combination with 
antibiotic alternatives like antimicrobial peptides and small molecules, would decrease 
the high concentrations of antibiotics required to treat infections, reducing the possibility 
of antibiotic resistance.9  
Bacterial cells within a population can become resistant to antibiotics through the 
following four mechanisms: antibiotic modification, decreased uptake, active site 
alterations, or alternate target production (Figure 1.1a).10 Ultimately, these resistant 
mechanisms can be horizontally transferred as genes through plasmids, spontaneous 
mutation, or inherited from other bacteria within the population (Figure 1.1b).3 In 
antibiotic modification, the antibiotic is changed via enzymatic cleavage. For example, 
increased β-lactamase production by a bacterial cell cleaves β-lactam antibiotics (i.e. 
penicillin derivatives), inactivating the antibiotic.10 In decreased uptake, bacteria can 
pump antibiotics out of the cytoplasm through efflux transport pumps located within the 
cell membrane.10 In active site alterations, bacterial cells can undergo changes to the cell 
membrane, which is a target of many antibiotics.10 Some strains of Escherichia coli and 
Staphylococcus aureus undergo changes in lipid or protein composition of the cell’s outer 
membrane, making diffusion of antibiotics difficult.11-13 Lastly, bacteria can produce 
alternative antibiotic targets, typically an enzyme or protein, which are resistant to 
antibiotic inhibition. The cell can continue to produce the original sensitive bacterial 
enzyme, which remains unaffected.14 This method of resistance is well known in 
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Methicillin Resistant S. aureus (MRSA) and Vancomycin Resistant S. aureus (VRSA).10, 
12  
 
Figure 1.1: (a) Mechanisms of antibiotic resistance10 and (b) horizontal gene transfer of 
resistance in a bacterial population.  
 
 
1.2.2 Bacterial Biofilms  
Biofilm formations of gram-positive and gram-negative bacteria, as well as fungi, 
have been isolated from immunocompromised patients (i.e. cystic fibrosis)15, 16 and 
medically implanted devices such as catheters, prosthetic heart valves, cardiac 
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pacemakers, and joint replacements.17-20 Typical pathogens isolated include, but are not 
limited to: S. aureus, Staphylococcus epidermidis, E. coli, Pseudomonas aeruginosa, and 
Candida albicans. The pathogenicity of these microorganisms is enhanced by the ability 
to form a biofilm on both biotic and abiotic surfaces, as well as antimicrobial resistance.21  
Biofilms are structured microbial communities that are irreversibly attached to 
either a living or non-living surface.22 Initially, individual, free-floating planktonic cells 
adhere to a surface. This is followed by the propagation stage, where cells spread across 
the surface and then enter a maturation stage, where the biofilm produces and is encased 
in an extracellular matrix. This excreted extracellular matrix, composed primarily of 
polysaccharides, proteins, and lipids,23 retains nutrients for the microbial cells and 
provides protection from antimicrobial treatments and the host immune system.17, 22, 23 
Cells within a biofilm display a distinctly different phenotype than their planktonic 
counterparts17, 22, 23 and are typically 1,000-fold more resistant than bacteria in a 
planktonic state, making treatment of these infections difficult.24  
The formation of a biofilm is controlled through the production of signaling 
molecules, called quorum-sensing molecules. Quorum sensing molecules are 
extracellular metabolites that relay information about cell density and can affect cell 
physiology.25, 26 This cell-to-cell signaling can lead to a coordinated dispersal event in 
which cells from the biofilm re-enter the planktonic state and colonize new surfaces 
within the body.22, 27 An accumulation of these small, diffusible molecules in the 
extracellular environment are essential for cell-to-cell communication, biofilm 
maintenance, and multicellular dispersion (Figure 1.2).28 
 5 
     
Figure 1.2: Steps in biofilm formation on a surface include: irreversible attachment of 
planktonic cells, bacteria replication and production of an extracellular matrix, and 
dispersal of planktonic cells.  
 
 
1.2.2.1 Biofilms in Cystic Fibrosis Patients  
Since biofilms are not limited to abiotic surfaces, they affect 
immunocompromised patients such as those with cystic fibrosis (CF). CF is a genetic 
disease that is characterized by gastrointestinal and pulmonary dysfunction that requires 
continuous medication and medical intervention.29 These dysfunctions are due to the 
excessive build up of thick mucus within the digestive tract and lungs. Due to the 
inability to remove excess mucus, bacteria located within the respiratory tract form 
biofilms on the surface of lung, leading to chronic infections.15, 16, 29 P. aeruginosa, a 
gram-negative bacteria, is the microbe that is typically isolated from the lungs of CF 
patients.16 In a healthy individual, the sterile environment of the lower respiratory tract is 
due to the natural production of periciliary fluid, a fluid that helps the lung clear mucus, 
microorganisms, and other debris.30, 31 Those with CF display excretions that lack 
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periciliary fluid, which causes endothelial damage and the extensive build up of mucus in 
the lungs.30, 31 
Current therapies for patients with CF involve both preventative and active 
treatment methods. Methods to facilitate the removal of the thick mucus within a CF lung 
are the most common preventative approaches. Here, patients can undergo chest 
physiotherapy, postural drainage, and high frequency chest compressions using a 
compression vest.29 The disruption of the mucus creates an environment less conducive 
to biofilm formation, while improving respiratory function by promoting ciliary 
clearance.29 Active treatments are necessary when CF lung is already infected by biofilms 
and require the use of systemic antibiotics.29 Unfortunately, systemic dosages of 
antibiotics often do not eradicate P. aeruginosa biofilms from the lung due to biofilm 
structure and acquired resistance from long term use.16 Over time, these chronic 
infections become more severe and difficult to manage and many CF patients are placed 
on a lung transplant list. Of those that do not receive new lungs, 80 to 95% of patients die 
as a result of lung damage and respiratory failure.32 Thus, the localized delivery of 
antimicrobial compounds directly to the lung of these patients may help reduce biofilm 
formation.  
 
1.2.2.2 Biofilms on Metallic Medical Devices  
Of the roughly 2.6 million annual orthopedic implant surgeries in the United 
States, approximately 112,000 result in infection.33 These orthopedic devices are 
typically made of stainless steel, titanium, or titanium alloys and when infected with 
bacteria or fungi they often need to be removed.33 Implant removal is typically 
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complicated by tissue or bone ingrowth.33, 34 The best approach to eradicate implant 
infections is to remove the initial implant, systemically treat the infection, and then insert 
a new implant.35, 36 These revision surgeries are painful, risky, and costly to the patient.33, 
34 
Although implant materials are sterilized prior to placement via aseptic technique, 
approximately 90% of all implants show pathogenic microorganisms on the surface post-
implantation.33 In vivo, implants are capable of absorbing host proteins, making the 
surface more favorable for microorganism attachment and subsequent biofilm growth.33 
S. aureus and S. epidermidis account for nearly 60% of all implant acquired infections.33, 
37 Since these bacteria are local to the surgical site, limiting initial bacterial attachment 
onto the implant surface may help to reduce biofilm formation.34 
 
1.3. Nitric Oxide: An Alternative Antimicrobial Compound  
1.3 .1 Nitric Oxide  
In 1992, Science named nitric oxide (NO) as the “molecule of the year,” for its 
role in biological messaging and signaling. Once thought to be a toxic chemical found in 
cigarettes and smog, NO is actually an effective regulator in the nervous, immune, and 
cardiovascular systems.38, 39 The list of processes that NO is associated with includes, but 
is not limited to: vasodilation,40, 41 cancer,42, 43 host infection,44, 45 and wound repair.46 
 
1.3.2 Endogenous Nitric Oxide Production 
Nitric oxide is produced endogenously in the body by the nitric oxide synthase 
(NOS) enzyme. NOS oxidizes the guanidine group of L-arginine; through the loss of five 
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electrons, NO is produced along with a stoichiometric equivalent amount of L-
citrulline.39, 47 The sustained formation of NO from NOS in macrophages and monocytes 
gives these cells the capability of being cytostatic and cytotoxic to various viruses, 
bacteria, fungi, and tumor cells.48 Macrophage production of glutathione, cysteine, 
peroxides, and superoxide, increases the antimicrobial effect of NO as NO readily reacts 
with thiols, such as those in glutathione and cysteine, to form S-nitrosothiols (RSNOs), 
capable of storing NO for longer periods of time.48 NO reacted with water, oxygen, and 
superoxide produce reactive intermediates, such as other radicals (NO2), anions of nitrite 
(NO2-) and nitrate (NO3-), various oxides (ex. N2O3), and peroxides (ONOO-)48. At lower 
pH, nitrous acid can form from accumulating NO2-, which can itself release NO when 
simultaneously oxidized and reduced. Individuals suffering from various bacterial or viral 
infections show elevated levels of nitrate in blood plasma, a byproduct of NO oxidation, 
indicating that cells are actively producing NO during infection.49  
 
1.3.3 Exogenous Nitric Oxide Donors   
Since endogenously produced NO plays such a crucial role in various biological 
systems, the delivery of exogenous NO holds promise for various biomedical applications 
including cardiovascular dilation, antimicrobial therapies, and tumoricidal treatments. 
Various donors have been synthesized to allow for controlled release of NO and include 
but are not limited to: nitrites, NO – metal complexes, nitroamines, N-diazeniumdiolates 
(NONOates), and RSNOs.44, 48 Each donor has properties and release profiles that make 
them unique and useful in various applications, but the most well studied donors are 
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NONOates and RSNOs (Table 1.1).50 These donors have functional groups available for 
linking to various biomaterials, including nanoparticles and hydrogels.  
 
Table 1.1: Comparison of the properties of two common NO donors: NONOates and 
RSNOs.51 
 
 
N-Diazeniumdiolates 
(NONOates) S-Nitrosothiols (RSNOs) 
Formation Conditions High Pressures of NO gas Acidic 
Decomposition Triggers H3O+ Light, heat, Cu2+, thiols 
Release kinetics Highly tunable based on pH Dependent on triggers 
Toxicity Carcinogenic nitrosamines None 
Charged Yes No 
Storage Capacity 2 moles NO/ mole 2° amine 1 mole NO/ mole thiol 
Light Sensitivity No Yes 
Source Exogenous Endogenous 
 
1.3.3.1 N-Diazeniumdiolates  
NONOates are the most widely used donors in NO releasing biomaterials.52 These 
donors release two moles of NO per parent compound under physiological conditions 
(i.e. 37°C, pH 7.4).  NONOates are formed via the reaction of a secondary amine with 
high pressures of NO gas.53 Successful NONOate formation requires the presence of a 
second basic residue, such as a metal alkoxide base (i.e. sodium methoxide), to 
deprotonate the secondary amine within the diazeniumdiolate backbone.51, 54 The 
diazeniumdiolate can then perform a nucleophilic attack of the NO.51, 54 The cation from 
the alkoxide base serves to stabilize the resulting anionic NONOate (Figure 1.3).53, 54  
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Figure 1.3: The formation of N-diazeniumdiolates. Two moles of NO are released from 
each NONOate species; these moieties are highlighted in purple.51, 54  
 
 
Upon protonation of the NO moiety on the NONOate donor, the NO is released.53 
However, the structure of the amine precursor directly affects the kinetics of this NO 
release. For example, diethylenetriamine NONOate (DETA/NONOate) has a half-life 
(t1/2) of 20 hours while diethylamine NONOate (DEA/NONOate) has a t1/2 of 2-4 
minutes.55, 56 The difference in NO release is due to hydrogen bonding stabilization from 
additional amines.51 Although NONOates are spontaneous NO donors under 
physiological conditions and have attractive amine functionalities, they are not produced 
naturally by the body and can decompose into potentially carcinogenic nitrosamines.57-60  
 
1.3.3.2 S-nitrosothiols  
RSNOs are attractive NO donors, as the body naturally produces a variety of 
RSNOs in human plasma, airway lining fluid, macrophages, neutrophils, and other sites 
relevant to the immune system, and are therefore non-toxic.44 Many small molecules and 
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proteins containing a thiol group can be nitrosylated, with the most common RSNO 
compounds of: S-nitrosocysteine, S-nitrosoglutathione, S-nitrosocysteamine, and S-
nitroso-N-acetylpencillamine (Figure 1.4).61 Molecules and proteins that contain thiol 
groups are preferably nitrosylated over those that contain nitrogen, carbon, and oxygen44. 
RSNO compounds are stable under physiological conditions (i.e. pH 7.4, 37°C), in the 
absence of light, and in the presence of transition metal chelators.44, 62 
 
Figure 1.4: S-nitrosocysteine (a), S-nitrosoglutathione (b), S-nitrosocysteamine (c), and 
S-nitroso-N-acetylpenicillamine (d) RSNO NO donors.  
 
 
  RSNOs can be formed in vitro by reacting a thiol-containing compound with a 
nitrosylating agent, such as alkyl nitrite, dinitrogen trioxide, or nitrous acid.63 The 
formation of these compounds is confirmed using ultraviolet-visible radiation (UV-Vis), 
as RSNO species absorb in both the visible (nN → π*; 550-600 nm) and ultraviolet (no → 
π*; 330-350 nm) ranges.64, 65  
  The decomposition mechanisms, as well as formation mechanisms, of these 
compounds make RSNOs excellent for the storage and transport of NO (Figure 1.5). The 
decomposition of a RSNO compound is due to the homolytic cleavage of the S–N bond, 
causing the release of NO and a thiyl radical.47, 62 This decomposition is triggered 
thermally, through photoinitiation, or through the addition of metal ions.47, 62 When the 
temperature of a RSNO is changed or is exposed to irradiation at the absorption 
maximum, the resulting decomposition releases NO and the resulting thiyl radical.47, 62, 64 
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Due to the very short life span of NO (3-5 seconds), it reacts almost immediately with 
oxygen (or superoxide in vivo) and becomes oxidized to form other reactive intermediates 
such as NO2-, OONO-, or NO3-, as previously mentioned.47 NO can also be released from 
RSNOs through the addition of copper (II) ions (Cu2+).62 Cu2+ readily reacts with thiolate 
(RS–), and through reduction, copper (I) ions (Cu+) are generated. The Cu+ reacts with the 
RSNO species to trigger the release of thiolate and NO, while simultaneously 
regenerating Cu2+. Buffers have enough Cu2+ to facilitate NO release from RSNO and 
ascorbate can also be added as a reducing agent in cases where the thiolate ion is low in 
concentration.62 RSNO compounds can also undergo transnitrosation, which involves the 
transfer of NO+ from a RSNO to an unreacted free thiol.62 This process impacts RSNO 
stability and results in the formation of a new R’SNO and thiol compound. This 
phenomenon is more relevant in vivo, where this transfer can modify cysteine residues 
and alter enzymes and active sites of proteins.62 
      
Figure 1.5: RSNO formation and resulting NO release mechanisms.66  
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1.3.4 Antibacterial Effect of Nitric Oxide  
The antibacterial effect of NO is due to the nitrosative and oxidative stress it 
causes in a virus or bacteria cell. NO can react with oxygen, water, and superoxide, as 
mentioned previously, to form highly reactive nitrogen and oxygen intermediates.67 The 
NO and the formed intermediates overwhelm the cell’s capability to remove these 
species, leading to damage of bacterial deoxyribonucleic acid (DNA), lipids, and 
proteins.67 The reactive nitrogen species are thought to cause the deamination of 
deoxynucleotides in DNA, disrupt the reactive sites of proteins, and damage cellular 
membranes through lipid peroxidation (Figure 1.6).68 NO and the resulting reactive 
species can also trigger biofilm dispersal. Here, planktonic bacterial cells are released 
from the biofilm and are then able to colonize other abiotic or biotic surfaces.69  
 
 
Figure 1.6: Cellular targets of endogenously and exogenously delivered NO (Image 
adapted from Carpenter et al.70). 
 
 
Recent work by Barraud et al. has shown that nanomolar (nM) concentrations of 
NO have been shown to decrease biomass and increase planktonic cell biomass of single 
and mixed biofilms containing E. coli, S. epidermidis, Vibrio cholera, C. albicans, and P. 
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aeruginosa.67, 71 A 500 nM concentration of the NO donor sodium nitroprusside (SNP) 
removed 38% of an established E. coli biofilm and 60% of the multi-species biofilm.71 
Additionally, Barraud and coworkers observed that nM concentrations of NO coupled 
with an antibiotic increased the effectiveness of the antibiotic through synergistic 
effects.67 The mechanism of biofilm dispersal is poorly understood, but is linked to 
nutrient availability, cell lysis within the biofilm, and release of quorum sensing 
molecules.67, 69 Upon dispersal, bacteria in a planktonic state are then more susceptible to 
antibiotic treatment.22  
 
1.4  Current Approaches to Nitric Oxide Delivery  
The potential of the antibacterial capability of NO is limited by storage and 
delivery methods.45, 72 Traditionally, NO has been delivered as a gas or through SNP, but 
NO delivery by nanoparticles and hydrogels is of recent interest due to the ability to 
deliver NO directly to the infection site.70  
 
1.4.1 Nitric Oxide Delivery by Nanoparticles  
Nanoparticles have been developed to deliver drugs and small molecules by 
injection, orally, and through inhalation.73-76 Inhaled nanoparticles have the potential to 
deliver drugs to patients with CF.77 There are several publications that discuss NO 
modified nanoparticles but a majority are based on gold and silica nanoparticles.24, 45, 57, 
72, 78-80 Polizzi and coworkers synthesized NONOate functionalized gold cluster 
nanoparticles capable of releasing micromole per milligram (µmole/mg) amounts of 
NO.79 The effectiveness of these particles was not tested against bacterial cultures or 
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biofilms, but sheds light on the true ability of NO release from nanoparticles. Perhaps the 
most well studied NO delivery vehicles are silica nanoparticles. Hetrick et al. modified 
aminopropyltrimethoxysiloxane nanoparticles with a NONOate moiety, capable of 
reducing P. aeruginosa, E. coli, S. aureus, S. epidermidis, and C. albicans biofilm growth 
by 99.9%.24, 45 Martinez and coworkers observed 100% killing of MRSA bacteria in the 
presence of NO releasing silicate nanoparticles81 while hydrogel/glass silicate 
nanoparticles synthesized by Friedman and coworkers showed 75-100% antibacterial 
activity against E. coli, Klebsiella pneumoniae, P. aeruginosa, and Streptococcus 
pyogenes.82 Although these nanoparticles are effective at biofilm eradication, Slomberg et 
al. showed cytotoxic effects of silica/NONOate nanoparticles against mouse fibroblasts.83 
Although these nanoparticles are antimicrobial and possess anti-biofilm properties, silica 
nanoparticles are not approved for use by the Food and Drug Administration (FDA) and 
thus have a limited application for drug delivery in humans.57  
While most publications focus on the use of silica nanoparticles, few utilize 
polymer nanoparticles to deliver NO. 84, 85 Poly(DL-lactic-co-gycolic acid) (PLGA), an 
FDA approved, biocompatible polymer was used by Yoo et al. and Nurhasni et al. to 
synthesize NO releasing nanoparticles.84-87 Yoo and coworkers utilized a water in oil in 
water (w/o/w) emulsion technique to encapsulate DETA/NONOate within the PLGA 
nanoparticles. Although these nanoparticles were not tested against bacterial cultures, 
they deliver µmole/mg amounts of NO in vitro.85 The PLGA nanoparticles developed by 
Nurhasni et al. also encapsulated a NONOate donor using an oil in water (o/w) 
emulsification technique. These nanoparticles released µmole/mg amounts of NO in vitro 
and showed approximately 99% killing of MRSA and P. aeruginosa.84  Although these 
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nanoparticles are non-cytotoxic and can ultimately be used in drug delivery applications 
in vivo, they utilize potential carcinogenic NONOate chemistry and not naturally derived 
RSNO donors. Thus, there is a need for a new biodegradable and biocompatible polymer 
nanoparticle that releases NO from RSNO donors.   
This project aims to improve upon current delivery methods of NO by utilizing 
RSNOs and biocompatible delivery vehicles. PLGA nanoparticles were functionalized 
with S-nitrosocysteamine at the surface to release amounts of NO that were bacteriostatic 
to bacterial cultures. These nanoparticles eliminate the issues of carcinogenic NONOates 
and utilize materials approved for use by the FDA. These nanoparticles could be effective 
for NO delivery to patients suffering from CF. 
 
1.4.2 Nitric Oxide Delivery by Metal Implants  
While nanoparticles have the potential to deliver NO directly to an infected lung, 
modification of metal surfaces to release NO can be used in medical device applications. 
Direct modification of a metallic surface to release NO was reported by Gallo and 
Mani.88 Here, cobalt-chromium stents were modified with phosphonoacetic acid, 
followed by DETA/NONOate. Although these stents were not tested against bacterial 
cultures, the modified metal surface released micromolar (µM) amounts of NO in vitro.88  
 Metallic implants that have been developed to release NO utilize polymeric 
coatings. Nablo and coworkers generated a stainless steel implant material coated with a 
silica sol-gel containing a NONOate donor.89 These coatings released picomole per cubic 
centimeter per second (pmole cm-2 s-1) amounts of NO over 24 hours, and reduced 
Staphylococcal bacterial adhesion onto the coated surface.89 Holt et al. coated the surface 
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of commercially pure titanium fixation pins utilizing a silica xerogel containing a 
NONOate functionality. Like Nablo and coworkers, these titanium pins released pmole 
cm-2 s-1 amounts of NO and reduced bacterial adhesion 48 days post implantation in a 
mouse model.89, 90 The cytotoxicity of these NONOate silica gel coatings was not 
discussed, and could pose limited applications for in vivo applications.89, 90   
In this project, a titanium alloy implant material was functionalized at the surface to 
release NO through a RSNO, S-nitroso-penicillamine. This donor eliminates the issues of 
carcinogenic NONOates, while being bacteriostatic against gram-positive and gram-
negative bacteria. The metal surface developed here is the first example of direct release 
of NO for bacterial inhibition from a metallic surface without the need for a polymeric 
coating.  
 
1.5 Summary  
Although systemic antibiotic usage continues to be the gold standard for the 
treatment of bacterial infections, the high antibiotic dosages required to achieve 
antimicrobial efficiency can lead to harmful toxicity and increased bacterial resistance.5 
Additionally, these high doses of antibiotics are ineffective against pathogenic biofilms 
that plague immunocompromised individuals and those with implanted medical devices. 
Localized delivery of antibiotics or antimicrobial alternatives, like NO, is needed to 
overcome the effects of antibiotic resistance. Antimicrobial delivery of NO through 
nanoparticles and metallic implant materials has shown to be effective against gram-
positive and gram-negative bacteria and fungi. These current delivery methods hold 
promise to deliver NO directly to the site of infection but unfortunately, have focused on 
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the use of potentially carcinogenic NONOates and scaffolds not approved for in vivo use 
by the FDA. The nanoparticles and titanium alloy developed here release NO amounts 
that are bacteriostatic against planktonic bacterial species and non-cytotoxic to 
mammalian cells, ideal for site specific delivery. 
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Chapter 2. Synthesis, Functionalization, Characterization, and 
Antimicrobial Activity of Poly(Lactic-co-Glycolic Acid) Nitric Oxide 
Releasing Nanoparticles  
 
2.1 Introduction 
 
PLGA nanoparticles are a promising platform technology for the controlled 
release of small molecule drugs.1 These nanoparticles are formed through emulsification 
and solvent evaporation techniques that encapsulates the molecule of choice into the 
center of the nanoparticle. Ultimately, the release of the encapsulated small molecule 
occurs either through diffusion of the molecule through the PLGA backbone, erosion of 
the polymeric material, or by combination of diffusion and erosion.1, 2 The advantage of 
using PLGA, in combination with a polymeric surfactant such as polyvinyl alcohol 
(PVA), over other platforms (i.e. silica nanoparticles), is that PLGA and PVA are 
biodegradable and biocompatible.1-4 PLGA degraded in vivo, enzymatically or non-
enzymatically, produces lactic acid and glycolic acid products that are also biocompatible 
and non-toxic.1, 2  
The formation of these polymer nanoparticles requires the presence of a 
surfactant, which itself is present on the exterior of the nanoparticle, while the PLGA 
remains on the inside of the nanoparticle. An oil/water emulsification technique is 
commonly used in nanoparticle synthesis, where the PLGA is dissolved first in solvent 
(oil phase) and then added to a water phase (surfactant in water). The two phases are 
homogenized together to produce microspheres and during the solvent evaporation 
process, the microspheres decrease in size as the solvent diffuses from the interior of the 
particle.1 The nanoparticles developed in this project utilize PVA as a surfactant, which 
presents free hydroxyl groups on the exterior of the nanoparticle, while the PLGA 
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remains on the interior of the nanoparticle (Figure 2.1a).3-5 These free hydroxyls are 
advantageous in that they can be functionalized by organic acid thin films (Figure 2.1b).6, 
7 These formed organic thin films mimic those of self-assembled monolayers (SAMs) 
which are ordered molecular assemblies formed spontaneously via chemisorption onto a 
specific substrate and are composed of a head group, alkyl chain, and a tail group.8, 9 The 
head group is thought to bind to an oxide rich surface through either ionic or covalent 
interactions.8 The tail group presents a reactive group that controls the interfacial 
properties and allows for modification to release a variety of bioactive compounds, such 
as DNA,3 antibiotics,6, 7 antimicrobial peptides,10 and cell adhesion peptides.11, 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: PLGA nanoparticles with PVA as the surfactant presents free hydroxyls at 
the surface (a) which allows for the formation of organic thin films at the surface (b).  
 
Functionalizing the surface of the nanoparticle has the advantage of direct 
delivery of bioactive compounds and is not dependent on the diffusion or the slow in vivo 
degradation of the PLGA and PVA. To date, there have been no surface functionalized 
PLGA nanoparticles developed that are capable of releasing NO. A majority of the 
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nanoparticles formulated to deliver NO focus on the use of silica nanoparticles and 
potentially carcinogenic NONOates.13-17 Here, PLGA/PVA nanoparticles were modified 
at the surface to release NO using organic thin films. A reaction at the thin film terminus 
provides an interface for further surface reactions in which an NO donor could be 
immobilized onto the surface. The functionalized nanoparticles were tested for 
antimicrobial properties and cytotoxic effects.  
 
2.2 Materials  
 
PLGA (50:50; 16.5-22 kDa; I.V. = 0.66-0.80) was purchased from Polysciences. 
Anhydrous dichloromethane (DCM, 99.9%) was purchased from Acros Organics and 
used as received. Cysteamine (95%), 16-phosphonohexadecanoic acid (COOH-Pa, 97%), 
N-Hydroxysuccinimide (NHS), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC), D-penicillamine (98-101%), sodium nitrite (NaNO2, 99.999% trace 
metal), and Dulbecco’s phosphate buffered saline (PBS, pH=7.4) were purchased from 
Sigma-Aldrich and used as received. Diethylenetriaminepentaacetic acid (DTPA, 
>99.0%) was purchased from Fluka. Polyvinyl alcohol (PVA, 86-89% hydrolyzed, low 
molecular weight) and hydrochloric acid (HCl) was obtained from Fisher Scientific. 
Methanol (100%) and deionized water (ddH2O) were obtained from Duquesne 
University. The nitrate/nitrite colorimetric assay kit was purchased from Cayman 
Chemical Company.  
Lennox Luria-Bertani (LB) Media was obtained from MP Biomedicals, Inc. and 
two capsules were dissolved per 50 mL of ddH2O and autoclaved before use. 
Tetracycline hydrochloride and tryptic soy broth (TSB) was obtained from Fisher 
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Scientific. Vancomycin hydrochloride (from Streptomyces orientalis) was obtained from 
Sigma-Aldrich. E. coli (ATCC® 25922), S. epidermidis (ATCC® 14990), 3T3 Swiss 
Albino mouse embryo fibroblasts (CCL-92), Dulbecco’s Modified Eagle’s Media 
(DMEM), fetal bovine serum (FBS), and penicillin/streptavidin were obtained from 
American Type Culture Collection (ATCC). Trypsin/EDTA was purchased from LONZA 
(Walkersville, MD). The LIVE/DEAD® Cytotoxicity/Viability Assay Kit for mammalian 
cells was purchased from Life Technologies/Fisher Scientific.  
 
2.3 Methods  
2.3.1 Nanoparticle Synthesis 
PLGA nanoparticles were prepared using an o/w solvent-evaporation technique 
with slight modifications from Mainardes et al. (Figure 2.2).18 Approximately 25 
milligrams (mg) of PLGA was added to 1 milliliter (mL) of DCM and was allowed to 
dissolve for one hour. A stock solution of 1% PVA was prepared by dissolving solid 
PVA in ddH2O, under heating and stirring conditions to facilitate the dissolving of the 
polymer. Ten mL of 0.3% PVA was added to the organic solution containing PLGA to 
form the o/w emulsion. The resulting emulsion was vortexed for 1 minute and then 
homogenized at 25,000 rpm for 2 minutes. The single emulsion was stirred for 4 hours to 
allow the DCM to evaporate. The particles were recovered by centrifugation (16,000 rcf) 
and washed twice with dH2O to remove excess PVA. The resulting nanoparticles were 
reconstituted in 5% w/v sucrose and lyophilized using a Labconco Freeze Dry System. 
Previous studies have shown that PLGA/PVA particle size and zeta potential remain 
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consistent after lyophilization.3 The lyophilized nanoparticles were stored in a desiccator 
until further reaction and characterization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: O/w emulsion technique for the synthesis of PLGA nanoparticles utilizing 
0.3% PVA as the surfactant. These polymer nanoparticles were formed via an o/w 
emulsification and solvent evaporation technique. 
 
 
2.3.2 S-Nitrosothiol Immobilization  
2.3.2.1 Thin-Film Surface Modification  
Prior to surface modification, the lyophilized nanoparticles were rinsed with PBS 
and recovered by ultracentrifugation to remove the sucrose cryoprotectant. Nanoparticles 
were suspended in a solution of 1 mM COOH-Pa in 25% methanol/ 75% water. The 
particles were allowed to react with COOH-Pa for 6 hours with gentle shaking at room 
temperature. The resulting suspension was centrifuged at 16,000 rcf for 20 minutes and 
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the collected nanoparticle pellet was dried in a desiccator overnight before further 
characterization and functionalization. 
 
2.3.2.2 S-Nitrosocysteamine Modified Nanoparticles   
S-Nitrosocysteamine (SNC), a RSNO NO donor, was immobilized onto the 
nanoparticle surface using a one-step approach (Scheme 2.1). SNC was generated by 
reacting cysteamine with acidified nitrite. Briefly, 100 mM of cysteamine was reacted 
with 100 mM NaNO2 and 250 mM HCl in the presence of 100 µM DTPA in an ice bath 
for 1 hour and 15 minutes, while protected from light (Scheme 2.1a).19 DTPA serves as a 
metal chelator and removes metals from the solution to avoid a premature release of NO 
from the solution.20 Once formed, SNC was attached to the nanoparticle surface using 
carbodiimide coupling. To form the amide bond, 200 µL of SNC, 200 µL 0.2 M NHS in 
ddH2O, and 100 µL 0.2 M EDC in ddH2O was added to the COOH-Pa modified particles 
and allowed to react for 24 hours in the dark under gentle shaking conditions (Scheme 
2.1b).21 The nanoparticles were collected by ultracentrifugation and allowed to dry in a 
desiccator at room temperature overnight before further experiments.   
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Scheme 2.1: The synthesis of the RSNO donor, SNC (a) and the reaction sequence for 
the immobilization of SNC to the surface of PLGA nanoparticles (b).  
 
2.3.2.3 S-Nitroso-Penicillamine Modified Nanoparticles  
S-Nitroso-penicillamine was immobilized onto the nanoparticle surface using a 
two-step approach (Scheme 2.2). The S-nitroso-penicillamine donor contains both amine 
and carboxylic acid functionalities within the molecule and thus the COOH-Pa 
nanoparticles were first activated with EDC and NHS, in the absence of the donor, to 
avoid any cross-linking within the RSNO donor (Scheme 2.2a). The COOH-Pa modified 
nanoparticles were reacted with 0.2 M NHS in ddH2O and 100 µL 0.2 M EDC in ddH2O 
for 7 hours in the dark under gentle shaking conditions. The particles were collected via 
ultracentrifugation and dried in a desiccator at room temperature overnight.  
S-nitroso-penicillamine was generated by reacting penicillamine with acidified 
nitrite. Briefly, 100 mM of penicillamine was reacted with 100 mM NaNO2 and 250 mM 
HCl in the presence of 100 µM DTPA in an ice bath for 1 hour and 15 minutes, protected 
from light (Scheme 2.2b).19 Once formed, 300 µL of S-nitroso-penicillamine added to the 
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EDC/NHS activated COOH-Pa nanoparticles and were allowed to react for 7 hours in the 
dark under gentle shaking conditions.21 The nanoparticles were collected by 
ultracentrifugation and allowed to dry in a desiccator at room temperature overnight 
before further experiments.   
 
 
Scheme 2.2: The synthesis of S-nitroso-penicillamine (a) and the reaction sequence for 
the immobilization of S-nitroso-penicillamine to the surface of PLGA nanoparticles (b).  
 
2.3.3 Characterization of Nanoparticles  
2.3.3.1 Infrared Spectroscopy  
A Nexus 470 Fourier Transform Infrared (FTIR, Thermo Fisher) spectrometer 
with a diffuse reflectance infrared Fourier transform (DRIFT) attachment was used to 
analyze the functional groups present at the surface of the nanoparticles both before and 
after functionalization with SNC and S-nitroso-penicillamine. A Thermo Nicolet 
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samples. Each sample was analyzed under inert conditions with 256 scans (4000 to 400 
cm-1) and a resolution of 4 cm-1. 
 
2.3.3.2 Ultraviolet-Visible Spectroscopy  
Liquid SNC and S-nitroso-penicillamine and modified nanoparticle solutions were 
scanned from 800 nm to 250 nm using a Varian UV-Vis spectrophotometer (Agilent 
Technologies, USA) to determine the wavelength of maximum absorption. The RSNO 
donors were diluted 1:1 with ddH2O to reduce signal saturation. To reduce colloidal 
interferences, the SNC and S-nitroso-penicillamine modified nanoparticles were 
dissolved in 2:1 DCM: methanol.22, 23 The attachment of both RSNO donors was 
confirmed through comparison of the UV-Vis spectrum of the liquid donor versus the 
UV-Vis spectrum of the dissolved nanoparticles.  
 
2.3.3.3 Scanning Electron Microscopy   
Morphological characteristics, such as shape and homogeneity, of unmodified and 
surface modified nanoparticles were examined using a Hitachi S-3400N-II scanning 
electron microscope (SEM) in backscatter electron mode. Micrographs were collected 
between 800-1100x magnification with a 5.00 kV accelerating voltage, 80.0 volt (V) 
probe current, and a working distance of 10.0 millimeters (mm). Samples were analyzed 
under variable pressure instead of full vacuum to reduce polymer melting.  
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2.3.3.4 Nanoparticle Size and Zeta Potential  
The nanoparticle size, polydispersity index (PDI), and zeta potential were 
determined using dynamic light scattering (DLS) on a Nano-ZS Zetasizer (Malvern, UK). 
DLS measures the average diameter of a spherical particle through Brownian motion, 
where large particles move slower than smaller particles. The resulting light intensity 
fluctuations are measured when exposed to a colloidal system (Figure 2.3a).24 Zeta 
potential is a measure of the charge of a nanoparticle surface, and is an indication of 
colloidal system stability and aggregation potential (Figure 2.3b). The larger the 
magnitude of the zeta potential, the greater the repulsive force within the system and 
therefore a smaller probability of particulate aggregation.25 For analysis, three replicates 
of five different nanoparticle samples were analyzed both for nanoparticle size and zeta 
potential. Nanoparticles were suspended in ddH2O and diluted 1:100 to fall into an 
appropriate range for the instrument.  
Figure 2.3: (a) Nanoparticle size determination via DLS, where resulting light intensity 
fluctuations are used to determine nanoparticle size. (b) Nanoparticle surface charge 
determination via zeta potential provides information regarding colloidal repulsion and 
aggregation. 
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2.3.4 Nitric Oxide Release Quantitation from Nanoparticles  
NO release from SNC modified nanoparticles was monitored using the Griess 
assay, purchased as a kit from Cayman Chemical.17, 26 The total concentration of NO 
released by a system is first measured through the conversion of NO3- to NO2- by nitrate 
reductase.27 This conversion is followed by the addition of the Griess reagents, which 
converts NO2- into a colored azo compound (Figure 2.4).27 The absorbance of this 
chromophore directly determines the concentration of NO2-, as it was converted from 
NO.27  
 
 
Figure 2.4: The quantitation of NO via the Griess Assay where the conversion from 
nitrate to nitrite (1) followed by reaction with the Griess reagents (2) forms a measurable 
chromophoric compound.  
 
NO release from nanoparticles was monitored over 48 hours. Briefly, 5 mg 
samples of nanoparticles were suspended in 1 mL PBS and placed on an incubator/shaker 
at 37°C, while protected from light. The addition of PBS begins the decomposition 
process of RSNOs so that the amount of NO released can be determined.28 At each time 
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preparation. The same volume of PBS that was removed at each time point was 
replaced.26  
The PBS supernatant samples were thawed and a 96-well plate was prepared per 
kit instructions. The assay included reagents that allowed for the construction of a 
nitrate/nitrite calibration curve. Briefly, 80 µL of sample was incubated with 10 µL of 
enzyme cofactor mixture and 10 µL of nitrate reductase mixture. After a 1-hour 
incubation, 50 µL of Griess Reagent R1 and 50 µL of Griess Reagent R2 were added to 
each well. The contents of the well were incubated at room temperature for 10 minutes 
before UV-Vis analysis. The 96-well plate was read using an Infinite M1000 microplate 
reader (Tecan, USA) at an absorbance of 540 nm. The concentration of NO was 
determined by information obtained by the calibration curve and equation provided by 
Cayman Chemical.27  
 
2.3.5 Antimicrobial Effects of S-Nitrosothiol Modified Nanoparticles  
2.3.5.1 Escherichia coli and Staphylococcus epidermidis Culture  
2.3.5.1.1 Escherichia coli Culture 
E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until 
use. To begin a culture, one full inoculation loop of E. coli was added to 10 mL of LB 
media in a T-25 cm2 culture flask. The E. coli flask was incubated overnight under 
shaking conditions at 37°C and diluted to an optical density at 600 nm (OD600nm) of 0.1 
before beginning bacterial assays.  
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2.3.5.1.2 Staphylococcus epidermidis Culture 
S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at 
-80°C until use. To begin a culture, one full inoculation loop of S. epidermidis was added 
to 10 mL of TSB media in a T-25 cm2 culture flask. The S. epidermidis was incubated 
overnight on a shaker incubator at 37°C and diluted to an OD600nm of 0.1 before 
beginning bacterial assays.  
 
2.3.5.2 Bacterial Turbidity Tests with Nanoparticles  
An analysis based on bacterial optical density was used to monitor the 
effectiveness of NO release against planktonic cultures of E. coli in LB media. The 
resulting overnight culture of E. coli was diluted to an OD600nm of 0.1 in LB media. SNC 
or S-nitroso-penicillamine nanoparticles were prepared at 10 mg/mL in PBS and 
unmodified nanoparticles were prepared as a control. To reduce colloidal interferences in 
the quantitation of the turbidity, a sterile 0.4 µm filter cell culture insert (Falcon, USA) 
was placed in each well and the 10 mg/mL nanoparticle suspension was placed inside the 
well insert. In this way, nanoparticles remained in the insert while the NO released by the 
nanoparticles could pass through the filter into the cell culture below. In each well of a 
24-well plate, 900 µL of the planktonic OD600nm E. coli culture was added. Six wells each 
contained: (i) E. coli + PBS, (ii) E. coli + unmodified nanoparticles, or (iii) E. coli + 
SNC/S-nitroso-penicillamine modified nanoparticles. The plate was placed in a shaker at 
37°C for 3 hours while protected from light. After incubation, the cell culture inserts with 
nanoparticles were discarded and the OD600nm was collected for each well using an 
Infinite M1000 PRO microplate reader, with unmodified LB media subtracted from each 
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well as the blank (n=6). Bacterial turbidity experiments involving S-nitroso-penicillamine 
modified nanoparticles were collected using a Varian UV-Vis spectrophotometer. 
 
2.3.5.3 Antibiotic Susceptibility Tests with Nanoparticles 
2.3.5.3.1 Determination of Effective Antibiotic Concentration  
A commonly prescribed antibiotic for E. coli infections, tetracycline, was chosen 
to test the synergistic effect of SNC nanoparticles.29, 30 Vancomycin, an antibiotic 
effective against gram-positive Staphylococci, was chosen for antibiotic susceptibility 
tests involving S. epidermidis.6, 31 To individual wells on a 48 well plate, concentrations 
of 500, 100, 50, 10, 1, 0.1, 0.05, and 0.01 µg/mL of tetracycline or vancomycin was 
added to 100 µL of E. coli or S. epidermidis and was diluted to a final volume of 200 µL 
with PBS (6 wells each, n=6). The plate was incubated at 37°C under shaking conditions, 
and the OD600nm was monitored each hour for 5 hours on the Infinite M1000 PRO 
microplate reader. A blank containing LB and the antibiotic was subtracted from each 
well. An antibiotic concentration that exhibits some inhibitory effect and is not 
completely inhibitory is necessary for this experiment.  
 
2.3.5.3.2 Antibiotic Susceptibility Test with Nanoparticles 
The initial E. coli and S. epidermidis culture was grown overnight and diluted to 
0.1 OD600nm as described previously. Unmodified and SNC/S-nitroso-penicillamine 
nanoparticles were prepared to a concentration of 10 mg/mL in PBS. As with the 
bacterial turbidity assay, a sterile 0.4 µm cell culture insert was placed in each well and 
the nanoparticle suspension was placed above the filter in the insert. To each of six wells, 
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900 µL of planktonic E. coli or S. epidermidis solution was placed in each well of a 24-
well plate, with: (i) E. coli/S. epidermidis + 100 µL PBS (ii) E. coli/S. epidermidis + 100 
µL tetracycline/vancomycin (iii) E. coli/S. epidermidis + 100 µL tetracycline/vancomycin 
+ unmodified nanoparticles or (iv) E. coli/S. epidermidis + 100 µL 
tetracycline/vancomycin + SNC/S-nitroso-penicillamine modified nanoparticles. The 
plate was incubated for 3 hours at 37°C under shaking conditions. The filter units were 
removed before analysis on the plate reader or UV-Vis at 600 nm (n=6). 
 
2.3.6 Cytotoxicity of Nanoparticles   
The cytotoxicity of the SNC nanoparticles was determined using 3T3 Swiss 
Albino mouse embryo fibroblasts. The cells were maintained in DMEM that was 
supplemented with 10% FBS and 1% penicillin/streptavidin. The fibroblasts were 
cultured until approximately 80% confluent and cells were removed from the flask by 
trypsinization. The suspended cells were diluted to a concentration of 10,000 cells per 
mL of fresh DMEM. Cut microscope slides were sterilized using 200-proof ethanol and 
UV light and were placed in each well of a 24 well plate and 1 mL of cell suspension was 
added to each well. The plate was incubated for 24 hours at 37°C in a 5% carbon dioxide 
environment. After 24 hours, the DMEM media was removed and replaced with 1 mL of 
fresh media. Cell culture inserts were added to each well and a 10 mg/mL suspension 
containing either SNC or unmodified nanoparticles in PBS was added to each well. PBS 
was added to each filter unit for control fibroblast samples. 
 After an additional 24 hour incubation, the number of live and dead fibroblast 
cells was determined using a Live/Dead® Viability/Cytotoxicity Kit from Invitrogen 
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(Figure 2.5). With this cytotoxicity kit, live cells fluoresce green, while dead cells 
fluoresce red. Five spots on each microscope slide with an area of 0.6 mm2 were imaged 
under 10x magnification using fluorescence filters on an Axioskop2 with AxioVision 
software. The number of live and dead cells was counted on 85 images for each sample 
and control. The percent viability for each condition was calculated using Equation 2.1 
and normalized to the fibroblast control.  
         
Figure 2.5: The fluorescent based Live/Dead® Viability/Cytotoxicity assay, where 
Calcein AM enters a viable cell, is converted to Calcein by cellular esterase. The Calcien 
enters the healthy cell’s nucleus and the cell fluoresces green. Ethidium homodimer 
enters a non-viable cell through the membrane, where it binds to DNA in the nucleus, and 
causes the cell to fluoresce red.    
 
 
Equation 2.1: !!!!!!Percent Viability % = Number of live cells 
Number of total cells (live+dead )
 
2.3.7 Statistics 
Statistical analysis was performed using Origin 8.0 software. A one way analysis 
of variance (ANOVA) with a Bonferroni post-hoc test was used to determine the 
averages and statistical significance of data at the p<0.05 level of significance, where 
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applicable. Outliers were determined by the Grubb’s test and excluded from presented 
data. All statistically analyzed data is presented as mean ± standard error. 
 
2.4  Results 
2.4.1   Nanoparticle Synthesis  
DRIFT spectroscopy was used to examine the surface chemistry of the PLGA 
nanoparticles (Figure 2.6). The surface of the unmodified nanoparticles included stretches 
characteristic of the PVA surfactant with peaks at 3343 cm-1 assigned to vO-H, 2942 cm-1 
indicative of the hydrocarbon backbone, 1452 cm-1 assigned to vC-OH, and 1267 cm-1 
assigned to vC-O. The peak in the spectrum at 1774 cm-1 can be attributed to the 
carboxylic acid groups within the PLGA core. Although many of these stretches overlap 
for PLGA and PVA, the broadness of vO-H indicates that the PVA surfactant dominates 
the nanoparticle surface with free hydroxyl groups, crucial for further functionalization.5      
 
Figure 2.6: DRIFT spectrum of unmodified PLGA(a)/PVA(b) nanoparticles, prepared 
using a o/w technique. The peak at 3343 cm-1 for vO-H indicates that free hydroxyls are 
present on the surface of the nanoparticles, and crucial for further NO functionalization.  
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2.4.2 S-Nitrosothiol Immobilization  
2.4.2.1 Thin Film Surface Modification  
After verification of nanoparticle synthesis, the nanoparticle surface was reacted 
with the COOH-Pa, a phosphonic acid, to deposit the organic film onto the surface of the 
nanoparticle. The addition of this organic acid presents a more reactive tail group, a 
carboxylic acid, at the nanoparticle surface.  
The CH2 stretching region of the DRIFT spectrum contains two peaks 
corresponding to the asymmetric and symmetric CH2 stretches, at 2913 and 2847 cm-1, 
respectively. When compared to COOH-Pa solid, these stretches confirm the presence of 
COOH-Pa on the nanoparticle surface (Figure 2.7a). Additionally, these peaks were not 
present initially in the DRIFT spectrum of the unmodified nanoparticles. The peak 
positions are indicative of a well-ordered film on the nanoparticle surface, characterized 
by alkyl chains in an all trans, crystalline-like conformation.8, 32  
It has been shown that when using organic acids with both carboxylic and 
phosphonic acid functional groups present at both termini, the thin film forms by utilizing 
the phosphonic acid as the head group, leaving the carboxylic acid group free at the 
nanoparticle surface for further reactions.6, 8, 33 The binding mode of COOH-Pa to the 
nanoparticle surface was also examined using DRIFT, where the solid COOH-Pa infrared 
spectrum is compared to that of the COOH-Pa modified nanoparticles (Figure 2.7b).6 The 
solid COOH-Pa spectrum contains peaks at 1214, 1077, 1008, 951, and 934 cm-1 
corresponding to the vP=O, vP-O, asym, vP-O sym, vP-OH, and vP-OH of the phosphonic acid head 
group, respectively. The DRIFT spectrum of COOH-Pa bound to the nanoparticle surface 
contains one broad peak at 1023 cm-1 for vP-O, combined with the loss of both vP-OH peaks 
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and the vP=O peak suggesting a tridentate binding mode. Here, all three oxygen atoms of 
the phosphonic acid head group is bound to the nanoparticle surface.6 
 
Figure 2.7: DRIFT spectra of the methylene stretching region of COOH-Pa on the 
nanoparticle surface (a) and the broad peak at 1023 cm-1 in the spectrum of the binding 
region of COOH-Pa confirms tridentate binding (b).   
 
 
2.4.2.2 S-Nitrosocysteamine Modified Nanoparticles: Attachment 
The immobilization of SNC was completed through amide bond formation using 
traditional carbodiimide coupling. The carboxylic acid group from the COOH-Pa thin 
film was first activated with EDC and NHS. The EDC and NHS act to generate a 
succinimidyl ester leaving group at the surface that readily reacts with primary amines to 
form amide bonds.34 Thus, the carboxylic acid group of COOH-Pa is first activated to a 
succinimidyl ester and then reacted with the primary amine within the SNC RSNO donor. 
The attachment of SNC to the nanoparticle surface was a “one pot” mixture, in which the 
nanoparticles were suspended in a solution containing EDC, NHS, and SNC 
simultaneously.21 Successful amide bond formation and presence of the NO group was 
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confirmed using DRIFT spectroscopy (Figure 2.8). The appearance of two peaks at 1650 
cm-1 for amide I (vC=O of amide) and 1565 cm-1 for amide II (vN-H of amide), both absent 
in unmodified nanoparticles, can be attributed to the formation of a secondary amide 
bond.6 The attachment of SNC is further confirmed by the appearance of the peak at 1506 
cm-1 that is indicative of the N=O stretch of NO and the presence of a peak at 714 cm-1 in 
the spectrum that is attributed to vC-S. 22, 23, 35  
                 
Figure 2.8: DRIFT spectrum of the attachment of SNC to the COOH-Pa modified 
nanoparticle surface as confirmed by the presence of amide I (1650 cm-1) and amide II 
(1565 cm-1), as well as the NO group at 1506 cm-1. 
 
UV-Vis spectroscopy was used in conjunction with DRIFT spectroscopy to 
confirm the successful attachment of SNC to the COOH-Pa thin film on the nanoparticle. 
Absorbance maxima at 334 nm and at 547 nm are indicative of electronic transitions of π → π* and nN → π*, respectively, for the SNO functionality as observed in pure, unbound 
SNC (Figure 2.9).22, 23, 36 The absorbance maximum at 334 nm was observed in the 
spectra of the dissolved SNC modified nanoparticles indicating successful 
immobilization of the NO donor onto the PLGA/PVA nanoparticles. The lack of the 
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nitrite and nitrous acid signatures in the original SNC donor and SNC modified 
nanoparticles indicates that no excess nitrite was present in the samples, crucial for the 
success of the NO release assay and antibacterial experiments.  
 
                       
 
Figure 2.9: UV-Visible spectra of SNC modified nanoparticles dissolved in 
DCM:Methanol, compared to the pure, unbound SNC donor. The wavelength of 
maximum absorbance at 334 nm for both the SNC modified nanoparticles and SNC 
liquid confirms successful nanoparticle functionalization. 
 
 
2.4.2.3 S-Nitroso-Penicillamine Modified Nanoparticles: Attachment 
The immobilization of S-nitroso-penicillamine was completed through amide 
bond formation using traditional carbodiimide coupling, as with SNC. However, in this 
reaction, the EDC and NHS were first reacted with the COOH-Pa modified nanoparticles 
to generate a succinimidyl ester leaving group at the surface because of the dual 
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penicillamine was then reacted with the EDC/NHS activated nanoparticles in a two-step 
process. The successful amide bond formation and presence of the NO group was 
confirmed using DRIFT spectroscopy (Figure 2.10). The appearance of two peaks at 
1651 cm-1 (C=O, amide I) and 1574 (N-H, amide II) cm-1, both absent in unmodified 
nanoparticles, can be attributed to the formation of the amide bond.6 The attachment of S-
nitroso-penicillamine is further confirmed by the appearance of the peak at 1508 cm-1 that 
is indicative of the N=O stretch of NO and the unreacted carboxylic acid group of S-
nitroso-penicillamine at 1748 cm-1. 
 
                            
 
Figure 2.10: DRIFT spectrum of the attachment of S-nitroso-penicillamine to the 
COOH-PA modified nanoparticle surface as confirmed by the presence of amide I (1651 
cm-1) and amide II (1574 cm-1).  The NO group is present at 1508 cm-1 and the stretch at 
1748 cm-1 indicates free carboxylic acid from S-nitroso-penicillamine.  
 
 
UV-Vis spectroscopy was used in conjunction with DRIFT spectroscopy to 
confirm the successful attachment of S-nitroso-penicillamine to the COOH-Pa thin film 
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electronic transitions of π → π* and nN → π*, respectively, for the SNO functionality as 
observed in pure, unbound S-nitroso-penicillamine (Figure 2.11).22, 23, 36 The absorbance 
maximum at 342 nm was observed in the spectra of the dissolved S-nitroso-penicillamine 
modified nanoparticles indicating successful immobilization of the NO donor onto the 
PLGA/PVA nanoparticles. The functionalization of the nanoparticle surface with S-
nitroso-penicillamine was less successful than that of the SNC donor, as seen by the 
spectral signatures around 350 nm. A significant amount of nanoparticles were dissolved 
to a collect a usable spectrum for the modification of nanoparticles with S-nitroso-
penicillamine. Thus, these nanoparticles were not characterized to the extent of the SNC 
nanoparticles and tested only against E. coli as a comparison in further experiments.  
                      
 
Figure 2.11: UV-Visible spectra of S-nitroso-penicillamine modified nanoparticles 
dissolved in DCM:Methanol, compared to S-nitroso-penicillamine liquid. The 
wavelength of maximum absorbance at 342 and 340 nm for both the S-nitroso-
penicillamine modified nanoparticles and S-nitroso-penicillamine liquid, respectively, 
confirms successful nanoparticle functionalization. 
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2.4.3 S-Nitrosocysteamine Modified Nanoparticles: Characterization 
Nanoparticle morphology and size was determined using SEM and DLS, 
respectively. Based on DLS, a heterogeneous size population was determined for 
unmodified nanoparticles while a monodisperse population for SNC modified 
nanoparticles. The average nanoparticle size for unmodified nanoparticles was 426.8 ± 
11.7 nm with a PDI of 0.210 ± 0.008 (Figure 2.12a) while surface functionalization 
increased nanoparticle size to 586.2 ± 14.3 nm (Figure 2.12a). The PDI of the SNC 
functionalized nanoparticles was 0.199 ± 0.012. This change in PDI is likely due to the 
loss of free hydroxyl groups at the nanoparticle surface, reducing the possibility of 
agglomeration. The same trend was also observed using SEM analysis, where 
nanoparticle size appears to increase after functionalization (Figure 2.12b). However, the 
nanoparticles appear to remain spherical after surface functionalization.  
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Figure 2.12: Nanoparticle size of unmodified and unmodified nanoparticles as 
determined by DLS (a) with corresponding SEM micrographs (b).  
 
Zeta potential was used to characterize the charge on the surface of both 
unmodified and SNC modified nanoparticles. The average zeta potential for unmodified 
and SNC nanoparticles was -20.9 ± 0.3 mV and -16.7 ± 0.4 mV, respectively (Figure 
2.13). The shift in zeta potential after SNC modification of the nanoparticles is likely due 
to the formation of amide bonds at the COOH-Pa tail, indicating that the nanoparticle 
surface was successfully functionalized.17, 37, 38 
 
50 µm 50 µm 
(a) 
(b) 
Unmodified Nanoparticles SNC Modified Nanoparticles 
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Figure 2.13: Zeta potential was determined using the Malvern Zetasizer, and indicates 
the charge on the nanoparticle surface. The slight shift towards a more positive zeta 
potential confirms functionalization of the nanoparticle surface. 
 
 
2.4.4 S-Nitrosocysteamine Modified Nanoparticles: Nitric Oxide Release 
 
The total amount of NO released per milligram of nanoparticles was determined 
using a nitrate/nitrite colorimetric assay (Griess Assay). NO degrades rapidly into nitrate 
under physiological conditions and thus in this assay, nitrates were converted to nitrites, 
and the total amount of nitrite was quantified. The total amount of NO, reflected from 
total nitrite, released by the nanoparticles cumulatively over a 48-hour time period was 
37.1 ± 1.1 nmol/mg of nanoparticles (Figure 2.14). The NO was burst released between 
the first and second hour of the assay, followed by a slow release of NO for the remainder 
of the assay. The maximum amount of NO released, 26.5 ± 1.0 nmol/mg, occurred at the 
two-hour time point. 
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Figure 2.14: Quantitation of NO release from SNC modified nanoparticles, determined 
using the colorimetric nitrate/nitrite Griess assay. The SNC modified nanoparticles 
released 37.1 ± 1.1 nmol NO/mg nanoparticles over a 48-hour time period. Each data 
point expresses the average NO release ± standard error (n=3).  
 
2.4.5 Bacterial Turbidity Tests with Nanoparticles  
2.4.5.1 S-Nitrosocysteamine Modified Nanoparticles  
The antibacterial activity of SNC modified nanoparticles was assessed by a 
bacterial turbidity E. coli challenge, where the planktonic growth of E. coli incubated 
with nanoparticles was monitored. The ability of the SNC NO donor to retain it’s 
antimicrobial ability after covalent attachment to the COOH-P thin film is important for 
localized, site specific treatment.10 Previous work suggested that nanoparticles added 
directly to the E. coli culture interfered with OD600nm measurements; therefore, filter cell 
culture inserts were added to each well to avoid nanoparticle dispersion into solution. The 
filter insert allowed NO to diffuse into the E. coli culture below without the dispersion of 
the nanoparticles. After incubating a 0.1 OD600nm E. coli culture with the nanoparticles 
for 3 hours, the OD600nm was collected for all E. coli controls and samples. The 
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normalized average OD600nm was 1.00 ± 0.02 for the E. coli control, 1.02 ± 0.08 for the 
unmodified nanoparticle control, and 0.681 ± 0.01 for the SNC modified nanoparticles 
(Figure 2.15). The OD600nm of the E. coli incubated with 10 mg/mL SNC modified 
nanoparticles was statistically lower than both the E. coli control and E. coli treated with 
unmodified nanoparticles. E. coli growth in the presence of SNC modified nanoparticles 
resulted in a 31.8 ± 0.7 % growth reduction compared to the E. coli control. This 
confirms that SNC is active after being immobilized to the nanoparticle surface. 
 
                          
Figure 2.15:  Bacterial turbidity assay of E. coli cultures treated with 10 mg/mL SNC 
modified nanoparticles shown as mean ± standard error, p<0.05. E. coli and E. coli 
treated with unmodified nanoparticles were not statistically different (#). E. coli 
inhibition by SNC modified nanoparticles is statistically different (*) than all other 
groups. 
 
2.4.5.2 S-Nitroso-Penicillamine Modified Nanoparticles  
The antimicrobial effect of the S-nitroso-penicillamine modified nanoparticles 
against E. coli was determined through a bacterial turbidity assay. After incubating a 0.1 
OD600nm E. coli culture with the nanoparticles for 2.5 hours, the OD600nm was collected 
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for all nanoparticle samples and E. coli controls. The average OD600nm was 1.00 ± 0.01 
for the E. coli control, 0.992 ± 0.02 for the unmodified nanoparticle control, and 0.864 ± 
0.01 for the S-nitroso-penicillamine modified nanoparticles (Figure 2.16). The OD600nm of 
the E. coli incubated with 10 mg/mL S-nitroso-penicillamine modified nanoparticles was 
statistically lower than both the E. coli control and E. coli treated with unmodified 
nanoparticles. E. coli growth in the presence of SNC modified nanoparticles resulted in a 
13.3 ± 2.6 % growth reduction compared to the E. coli control. As confirmed by DRIFT 
and UV-Vis spectroscopy, these nanoparticles likely release less NO because of non-
optimized attachment conditions and are therefore less antimicrobial.   
 
                            
Figure 2.16:  Bacterial turbidity assay of E. coli cultures treated with 10 mg/mL S-
nitroso-penicillamine modified nanoparticles shown as mean ± standard error, p<0.05. E. 
coli and E. coli treated with unmodified nanoparticles were not statistically different (#). 
E. coli inhibition by S-nitroso-penicillamine modified nanoparticles is statistically 
different (*) than all other groups. 
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2.4.6 Antibiotic Susceptibility Tests with Nanoparticles 
 
2.4.6.1 S-nitrosocysteamine Nanoparticles and Escherichia coli  
The synergistic effect of an antibiotic with a low concentration of NO was tested 
with tetracycline, as it is an effective antimicrobial against gram-negative bacteria. The 
concentration of tetracycline used was 100 ng/mL, as determined by testing various 
concentrations of tetracycline against E. coli (Figure 2.17). This concentration only 
reduced bacterial growth but is not considered fully inhibitory against E. coli.29  
 
Figure 2.17: (a) Concentrations of tetracycline tested against E. coli to determine an 
appropriate concentration to test for the synergistic effect with SNC modified 
nanoparticles. The desired concentration should be slightly inhibitory as to still promote 
the growth of E. coli. (b) 100 ng/mL tetracycline was selected as the concentration to be 
utilized in antibiotic susceptibility assays.   
 
 After three hours, the normalized average OD600nm for E. coli without tetracycline 
was 1.00 ± 0.03, E. coli treated with 100 ng/mL tetracycline had an OD600nm of  0.738 ± 
0.07, the average OD600nm for E. coli in the presence of unmodified nanoparticles and 
tetracycline was 0.517 ± 0.09, and the average OD600nm for E. coli cultures in the 
presence of SNC modified nanoparticles and tetracycline was 0.0836 ± 0.02 (Figure 
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2.18). The OD600nm of E. coli incubated with 10 mg/mL SNC modified nanoparticles and 
tetracycline was statistically lower than the E. coli controls and E. coli treated with 
unmodified nanoparticles, indicating successful bacterial inhibition. The addition of SNC 
nanoparticles to an antibiotic increases the effectiveness of tetracycline by 87.8 ± 3.3 %.    
 
                             
Figure 2.18: Antibiotic susceptibility challenge in the presence of E. coli cultures treated 
with 100 ng/mL tetracycline and 10 mg/mL SNC modified nanoparticles, shown as mean 
± standard error, p<0.05. E. coli treated with tetracycline and E. coli treated with 
unmodified nanoparticles and tetracycline were not statistically different (#). E. coli 
treated with SNC modified nanoparticles and tetracycline is statistically different (*) than 
all other groups. 
 
2.4.6.2 S-Nitroso-Penicillamine Modified Nanoparticles and  
Escherichia coli  
 
The S-nitroso-penicillamine modified nanoparticles were combined with 100 
ng/mL tetracycline to observe the synergistic effect of the NO released from these 
nanoparticles with an antibiotic. These nanoparticles exhibited less of an antimicrobial 
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penicillamine modified nanoparticles would not show as significant of a synergistic 
effect.  
After 2.5 hours, the normalized average OD600nm for E. coli without tetracycline 
was 1.00 ± 0.02, E. coli treated with 100 ng/mL tetracycline had an OD600nm of  0.466 ± 
0.004, the average OD600nm for E. coli in the presence of unmodified nanoparticles and 
tetracycline was 0.452 ± 0.006, and the average OD600nm for E. coli cultures in the 
presence of S-nitroso-penicillamine modified nanoparticles and tetracycline was 0.404 ± 
0.003 (Figure 2.19). The OD600nm of E. coli incubated with 10 mg/mL S-nitroso-
penicillamine modified nanoparticles and tetracycline was statistically lower than the E. 
coli controls and E. coli treated with unmodified nanoparticles, indicating successful 
bacterial inhibition. However, the addition of S-nitroso-penicillamine nanoparticles to 
reduces bacterial growth by 13.2 ± 1.5 %, indicating a limited synergistic effect. The 
concentration of NO released from the nanoparticle surface is likely too low to exhibit the 
desired synergistic effect.  
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Figure 2.19: Antibiotic susceptibility challenge in the presence of E. coli cultures treated 
with 100 ng/mL tetracycline and 10 mg/mL S-nitroso-penicillamine modified 
nanoparticles, p<0.05. E. coli treated with tetracycline and E. coli treated with 
unmodified nanoparticles and tetracycline were not statistically different (#). E. coli 
treated with S-nitroso-penicillamine modified nanoparticles and tetracycline is 
statistically different (*) than all other groups. 
 
2.4.6.3 S-Nitrosocysteamine Modified Nanoparticles and Staphylococcus 
epidermidis 
 
 The SNC modified nanoparticles when in combination with tetracycline 
exhibited a synergistic effect. The same effect was tested with S. epidermidis in the 
presence of a gram-positive effective antibiotic, vancomycin. The concentration of 
vancomycin used was 5 µg/mL, as determined by testing various concentrations of 
vancomycin against S. epidermidis (Figure 2.20). This concentration reduced bacterial 
growth slightly but is not considered fully inhibitory against S.epidermidis.29 
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Figure 2.20: (a) Concentrations of vancomycin tested against S. epidermidis to determine 
an appropriate concentration to test for the synergistic effect with SNC modified 
nanoparticles. The desired concentration should be slightly inhibitory as to still promote 
the growth of S. epidermidis. (b) 5 µg/mL vancomycin was selected as the concentration 
to be utilized in antibiotic susceptibility assays.   
 
After three hours, the normalized average OD600nm for S. epidermidis without 
vancomycin was 1.00 ± 0.01, S. epidermidis treated with 5 µg/mL vancomycin had an 
OD600nm of 0.742 ± 0.03, the average OD600nm for E. coli in the presence of unmodified 
nanoparticles and vancomycin was 0.433 ± 0.01, and the average OD600nm for S. 
epidermidis in the presence of SNC modified nanoparticles and vancomycin was 0.372 ± 
0.01 (Figure 2.21). The OD600nm of S. epidermidis incubated with 10 mg/mL SNC 
modified nanoparticles and vancomycin was not statistically different than the S. 
epidermidis cultures treated with unmodified nanoparticles and vancomycin, indicating 
no synergistic effect against a gram-positive bacteria species. Additionally, the S. 
epidermidis treated with vancomycin control and the S. epidermidis treated with 
unmodified nanoparticles and vancomycin were not statistically the same, indicating that 
1 2 3 4 5
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
0.22
0.24
O
pt
ic
al
 D
en
si
ty
 a
t 6
00
 n
m
Time (hours)
 500 ug/mL
 100 ug/mL
 50 ug/mL
 10 ug/mL
 1 ug/mL
 0.1 ug/mL
 0.01 ug/mL
 0.05 ug/mL
 0 ug/mL
1.0 1.5 2.0 2.5 3.0 3.5 4.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
O
pt
ic
al
 D
en
si
ty
 a
t 6
00
 n
m
Time (Hours)
 S. epidermidis
 5 µg/mL Vancomcycin
(a) (b) 
 60 
S. epidermidis are likely adhering the filter units and is removed from the culture, 
reducing the OD600nm. 
 
              
Figure 2.21: Antibiotic susceptibility challenge in the presence of S. epidermidis cultures 
treated with 5 µg/mL vancomycin and 10 mg/mL SNC modified nanoparticles, shown as 
mean ± standard error, p<0.05. S. epidermidis treated with SNC modified nanoparticles 
and vancomycin  and S. epidermidis treated with unmodified nanoparticles and 
vancomycin were not statistically different (#), indicating no synergistic effect. The 
vancomycin controls were statistically different (*), indicating that S. epidermidis cells 
were likely adhering to the filter unit.  
 
 Due to lack of a synergistic effect with a gram-positive bacterium, vancomycin, 
and SNC modified nanoparticles, a 0.1 OD600nm culture of S. epidermidis was treated with 
100 µM of unbound, pure SNC. The resulting OD600nm for the S. epidermidis control was 
1.00 ± 0.01 and 0.785 ± 0.02 for S. epidermidis treated with the SNC donor (Figure 2.22). 
The SNC liquid treated S. epidermidis is statistically different from the S. epidermidis 
control, but even at µM concentrations, SNC is not very antimicrobial against this gram-
positive bacterium. Thus, nM concentrations of NO released from the SNC nanoparticles 
would not inhibit S. epidermidis growth.  
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Figure 2.22:  Bacterial turbidity assay of S. epidermidis cultures treated with 100 µM 
SNC liquid shown as mean ± standard error, p<0.05. S. epidermidis and S. epidermidis 
treated SNC were statistically different (*), indicating some inhibition. 
 
2.4.7 Cytotoxicity of Nanoparticles   
The cell viability of NIH3T3 fibroblasts treated with SNC nanoparticles was 
determined by the Live/Dead® Viability/Cytotoxicity Assay. Live and dead cells were 
counted on each microscope image and the average percent viability was calculated.39 
The resulting data was normalized to the fibroblasts treated with PBS. The normalized 
average percent cell viability for fibroblasts grown in the presence of PBS, unmodified 
nanoparticles, and SNC modified nanoparticles was 100.0 ± 2.2 %, 103.2 ± 2.2 %, and 
100.8 ± 3.7 %, respectively (Figure 2.23). Fibroblasts treated with SNC nanoparticles had 
statistically the same percent cell viability as both controls, indicating that 
functionalization of the surface to release NO did not cause the nanoparticles to be 
cytotoxic to mammalian cells.   
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Figure 2.23: Normalized average percent cell viability of NIH3T3 mouse embryo 
fibroblasts grown in the presence of PBS, unmodified nanoparticles, and SNC modified 
nanoparticles. Data is shown as mean ± standard error, p<0.05. Fibroblast growth was not 
statistically different between controls and nanoparticle samples. The Live/Dead images 
of the NIH3T3 fibroblasts are below, from left to right: fibroblast control, fibroblasts 
treated with unmodified nanoparticles, and fibroblasts treated with SNC modified 
nanoparticles.  
 
 
2.5  Discussion 
RSNO donors have been previously incorporated into silica particles40 but have 
not been immobilized on polymer nanoparticles using thin film modification techniques. 
Additionally, most work involving nanoparticles utilizes potentially carcinogenic N-
diazeniumdiolate chemistry.13-16, 41, 42 Here, we investigated the release of NO from 
functionalized PLGA nanoparticles to reduce E. coli growth and increase the 
effectiveness of an antibiotic, as NO has been shown to be an effective antimicrobial 
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agent against planktonic and biofilm bacterial growth. These polymer nanoparticles have 
the potential to be delivered via aerosol methods to the lungs, especially in patients with 
CF, where bacterial biofilms can have detrimental effects.  
The nanoparticle surface was first modified with a COOH-Pa thin film. The 
phosphonic acid head group of the organic acid was successfully bound to the 
nanoparticle surface using the free hydroxyl groups present on the nanoparticle surface 
from the PVA surfactant. The CH2 stretches within the DRIFT spectrum indicate that the 
COOH-Pa molecules presented on the surface are alkyl-chain ordered, giving optimal, 
crystalline packing of these molecules on the surface (Figure 2.7a). COOH-Pa was bound 
to the surface in a tridentate manner with all three oxygen atoms bound to the 
nanoparticle (Figure 2.7b).6  
The free carboxylic acid tails, as well as any accessible carboxylic acid groups 
from the PLGA nanoparticle core, are available for carbodiimide coupling with the 
primary amine functionality within SNC and S-nitroso-penicillamine. The appearance of 
two stretches indicative of amide I and amide II bond formation in the infrared spectra 
indicate successful SNC (Figure 2.8) and S-nitroso-penicillamine (Figure 2.10) 
attachment to the surface. Additionally, the NO moiety appears in the infrared spectra, 
further verifying the presence of SNC and S-nitroso-penicillamine on the nanoparticle 
surface.  
Attachment was also confirmed using UV-Vis spectroscopy. The SNC and S-
nitroso-penicillamine modified nanoparticles dissolved in DCM:methanol had the same 
spectral signature as pure, unbound SNC (Figure 2.9) and S-nitroso-penicillamine (Figure 
2.11). Unfortunately, there appears to be less NO on the surface of S-nitroso-
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penicillamine modified nanoparticles, because a higher concentration of nanoparticles 
were required to obtain an interpretable UV-Vis spectrum. With this higher concentration 
of particles, interferences from the PLGA and PVA are present around 350 nm. Due to 
the two-step preparation process of the S-nitroso-penicillamine nanoparticles, it was 
likely that optimal activation of the carboxylic acid tail of COOH-Pa was not achieved, 
ultimately leading to less S-nitroso-penicillamine attachment. Thus, these S-nitroso-
penicillamine nanoparticles were not characterized further, and used only for a 
comparison of antimicrobial activity.  
Overall, the spectra of both the unbound liquid SNC and SNC modified 
nanoparticles lack contributions from excess nitrite and nitrous acid from the synthesis 
step,43 allowing for NO quantification using the Griess assay17. From this assay, it was 
determined that 37.1 ± 1.1 nmol of NO was released per mg of SNC nanoparticles, 
similar to what has been reported in other RSNO modified nanoparticles (Figure 2.14).17 
The carboxylic acid groups within the PLGA core of the nanoparticles may have been 
nitrosylated, allowing for the extended release of NO over the 48 hours of the assay. 
There was a change in both nanoparticle size and zeta potential after modification 
of the nanoparticles with SNC, indicating successful modification (Figure 2.12). The size 
of the SNC modified nanoparticles is larger than the unmodified nanoparticles, since 
another layer is added when the nanoparticles are modified with COOH-Pa and SNC, 
which is consistent with previous work by Sperling et al. and Pellegrino et al.44, 45 The 
developed SNC modified nanoparticles are larger than other NO delivering nanoparticle 
systems, such as silicon and gold.14, 15, 17, 46 but other systems are not made of 
biodegradable polymers suitable for biomedical applications. However, the size of the 
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nanoparticles is still at a size that could be utilized for inhalation drug delivery.47, 48 The 
zeta potential of the SNC modified nanoparticles shifts slightly more positive, likely due 
to the reduction of the free hydroxyl groups present on the nanoparticle surface (Figure 
2.13). However, the zeta potential remains negative overall, an indication of the 
electrophilic molecule S-nitrosation at the surface.17  
The nanomolar amount of NO released from the SNC nanoparticles has a 
bacteriostatic effect on E. coli cultures, as observed from the bacterial turbidity assay and 
antibiotic susceptibility challenge. E. coli growth was inhibited 31.8 ± 0.7 % when 
treated with 10 mg/mL SNC nanoparticles, which is significantly different than controls 
(p<0.05) (Figure 2.15). The S-nitroso-penicillamine modified nanoparticles inhibited E. 
coli growth by 13.2 ± 1.5 %, which is significantly different from the other E. coli 
controls (p<0.05), but is not as bacteriostatic as the SNC modified nanoparticles (Figure 
2.16). This further confirms the results obtained by the UV-Vis spectroscopy, as there is 
likely less NO on the surface of the S-nitroso-penicillamine modified nanoparticles.  
A synergistic effect of NO and an antibiotic against P. aeruginosa was observed 
by Barraud et al.29 In this antibiotic susceptibility assay, a small concentration of the 
antibiotic tobramycin and a nM amount of sodium nitroprusside were incubated with 
planktonic cultures of P. areuginosa.29 The resulting bacterial culture showed a 2-log 
decrease in growth (via a colony forming units assay) compared to just the antibiotic 
alone, indicating that NO increased the effectiveness of an antibiotic.29 The SNC 
nanoparticles developed here offered a synergistic effect against E. coli when coupled 
with 100 ng/mL tetracycline, resulting in a 87.8 ± 3.3 % reduction in growth when 
compared to E. coli cultures treated only with tetracycline (p<0.05) (Figure 2.18). This is 
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advantageous because these nanoparticles are capable of increasing the effectiveness of 
antibiotics, thus less antibiotic would be needed to treat a bacterial infection and 
subsequently reduce the risk of antibiotic bacterial resistance. NO is thought to change 
the physiology of bacterial cells, making them more susceptible to antibiotics.29 The S-
nitroso-penicillamine exhibited only a bacteriostatic effect against E. coli and did not 
significantly increase the effectiveness of tetracycline (Figure 2.19). This was likely due 
to the limited attachment of S-nitroso-penicillamine to the nanoparticles, where less NO 
is released from the surface.  
Unfortunately, the SNC modified nanoparticles when coupled with vancomycin 
did not exhibit a synergistic effect against S. epidermidis (Figure 2.20). A larger 
concentration of NO delivered from 100 µM of liquid SNC showed limited bacterial 
inhibition of S. epidermidis (Figure 2.21), indicating that the amount of NO being 
released from the nanoparticles was not enough to reduce bacterial growth. Gram-
positive bacteria are capable of producing their own NO through bacterial NOS and as 
shown by Gusarov et al., NO production in a gram-positive bacterial cell increases as 
bacterial cells are subjected to an antibiotic.49 Thus, the endogenously delivered nM 
amounts of NO in the presence of vancomycin does not inhibit bacterial growth because 
the bacteria in the population are already making their own NO.49 
To consider these nanoparticles as a NO delivery vehicle in vivo, they should not 
elicit cytotoxic effects against mammalian cells in vitro. Though the SNC modified 
nanoparticles inhibit bacterial cells, they should not inhibit NIH3T3 fibroblast growth. 
The SNC modified nanoparticles showed no cytotoxic effect to fibroblasts after 24 hours, 
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as the percent viability of fibroblasts treated with SNC nanoparticles, unmodified 
nanoparticles, and PBS were all statistically the same (p<0.05) (Figure 2.22).  
 
2.6  Conclusions 
PLGA nanoparticles with PVA surfactant were developed using a o/w emulsion 
technique, in which the PLGA was encapsulated on the interior of the nanoparticles and 
the PVA presented hydroxyl groups on the exterior of the nanoparticle. The hydroxyl 
groups were reacted with an organic acid to form a functional thin film on the 
nanoparticle surface. The organic acid presented a more reactive carboxylic acid 
functional group at the surface, allowing for amide bond formation between two RSNO 
NO donors containing a primary amine: S-nitrosocysteamine and S-nitroso-penicillamine 
(Figure 2.24).   
     
Figure 2.24: PLGA/PVA nanoparticles were modified with a phosphonic acid thin film 
and then functionalized at the tail group to immobilize (a) SNC or (b) S-nitroso-
penicillamine. 
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DRIFT and UV-Vis analysis was used to confirm RSNO attachment to the 
nanoparticle surface and DLS, SEM, and zeta potential was utilized to characterize size, 
morphology, and zeta potential, respectively, of the functionalized nanoparticles. The 
nanoparticles released nM amounts of NO in vitro and were bacteriostatic against E. coli 
cultures, while increasing the effectiveness of an antibiotic. The low concentration of NO 
released from the nanoparticle surface was not enough to inhibit S. epidermidis growth, 
as Staphylococci species are capable of producing their own NO. These nanoparticles 
were non-cytotoxic to mammalian cells and offer the potential deliver NO directly to an 
infection site (i.e. bacterial growth in the lungs), while reducing the amount of antibiotic 
needed, limiting the possibility of antibiotic resistance.  
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Chapter 3: Functionalization, Characterization, and Antimicrobial 
Activity of Nitric Oxide Releasing Titanium-Aluminum-Vanadium 
Alloy  
 
3.1 Introduction 
Titanium and its alloys have been utilized as a joint replacement material for 
dental, cardiovascular, and structural applications, due to strength of the materials, 
biocompatibility and corrosion resistance. Titanium-aluminum-vanadium (Ti-6Al-4V) 
alloy was developed as an alternative to commercially pure titanium as it has an increased 
elastic modulus, yield strength, and ultimate strength, factors important for the 
development of a metallic implant material.1, 2 Additionally, Ti-6Al-4V implant materials 
are favored over stainless steel and cobalt-chromium materials because it has a stiffness 
closer to that of natural bone, resulting in less stress shielding of bone when implanted.3 
The biocompatibility and corrosion resistance of Ti-6Al-4V is due to the thin, but 
strongly adhered oxide layer that instantaneously occurs after the alloy is exposed to 
oxygen or water.4, 5 This oxide coating serves as a protective layer against the attack of 
corrosive forces, such as biological proteins, salts, water, and oxygen.5, 6  
Ti-6Al-4V implant materials are utilized in hip joint and knee joints, where hard 
tissue has failed.3 In these applications, tissue regeneration and osseointegration is 
important to reduce implant wear, rejection, and failure.2, 7 Implant rejection and failure 
can also result from infection.3, 8, 9 If bacterial adhesion occurs before the tissue 
regeneration process takes place after implantation, the host defense cannot prevent the 
surface colonization of bacteria, potentially leading to biofilm formation and infection.3 
Thus, inhibiting initial bacterial adhesion through anti-infective implant materials would 
be essential to preventing implant failure and rejection.3 Antimicrobial compounds, such 
 74 
as antibiotics,10-13 metal ions,14 and antimicrobial peptides,15, 16 have been presented at the 
surface of metal and ceramic biomaterials using synthetic and natural polymeric coatings, 
physisorption, and SAMs to reduce bacterial adhesion and colonization. Gao and 
coworkers developed a hydrophilic siloxane polymer coating on the surface of Ti-6Al-4V 
that chemically cross-linked various antimicrobial peptides to reduce bacterial adhesion.17 
Others have utilized naturally antimicrobial polymeric coatings, such as chitosan and 
fibronectin, to reduce bacterial adhesion to implant materials.18-20 The presentation of 
antimicrobial metal ions, such as copper, silver, and zinc, at the implant surface can also 
reduce bacterial adhesion by damaging a bacterial cell membrane upon contact.21 These 
metal ions have also been incorporated into polymeric coatings at the surface of the 
implant material.22 These aforementioned approaches chemically alter the outermost 
layer of the metallic biomaterial while preserving the physical properties of the implanted 
metal material below.23  
SAMs are ordered molecular assemblies that form spontaneously via 
chemisorption onto an oxide rich material and are composed of a head group, alkyl chain, 
and a tail group.24, 25 Monolayer formation begins when the head group of an individual 
molecule binds to the oxide rich layer of a metal or metal alloy surface (Figure 3.1a).25 
Formation and growth of a monolayer occurs when additional organic acid molecules 
react with the surface, aggregate into islands, and islands coalesce over time while the 
alkyl chains align to form an ordered film of molecules (Figure 3.1b).24, 26, 27 
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                                     (a)             (b) 
 
Figure 3.1: SAM molecule interacting with the metal oxide surface (a) and growth of a 
SAM via island formation and aggregation.  
 
 The choice of head group is crucial for SAM stability and those formed from 
aliphatic molecules containing a phosphonic acid head group adhere more strongly to 
metal alloy oxide surfaces than molecules containing a carboxylic acid, sulfonic acid, or 
hydroxamic acid.25 The long aliphatic alkyl chains of SAMs promote order and further 
stabilization through van der Waals interactions within the carbon chain backbone.25, 28-31 
Ordered films that contain alkyl chains with greater than twelve carbons typically adopt 
an all trans configuration, and are considered crystalline in structure (Figure 3.2a). Alkyl 
chains with less than twelve carbons typically form disordered monolayers on the metal 
oxide surface and present a liquid-like structure with gauche interactions. These 
interactions minimize the amount of van der Waals forces that occur between the 
neighboring carbon chains (Figure 3.2b).31, 32 The SAM can be further stabilized through 
hydrogen bonding interactions between the tail groups of neighboring molecules within 
the SAM.33 These tail groups ultimately control the interfacial properties at the surface 
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and can be utilized for further surface reactions, such as through the immobilization of 
bioactive molecules. 2, 10-12, 16, 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: (a) SAMs can form in an ordered, crystalline all trans configuration 
monolayer or (b) in a disordered liquid-like monolayer with gauche interactions.  
 
Functionalizing the surface of Ti-6Al-4V metal implant materials has the 
advantage of direct delivery of antimicrobial compounds to a potential infection site, 
specifically the site of surgical implantation. To date, there have been no reports of 
covalent immobilization of NO releasing molecules to the surface of Ti-6Al-4V for 
antimicrobial applications. Stainless steel 316L and cobalt-chromium metallic implant 
materials have been developed to deliver NO through physisorption35 or polymeric 
coatings,36, 37 but utilize potentially carcinogenic NONOates in all cases. Here, Ti-6Al-4V 
was modified to release NO from a SAM containing a phosphonic acid head group and 
carboxylic acid tail group. A reaction at the monolayer terminus provides an interface for 
further surface reactions in which a RSNO NO donor could be immobilized onto the 
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Bulk Metal
Metal Oxide
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surface. The functionalized Ti-6Al-4V substrates were tested for antimicrobial properties 
and cytotoxic effects.  
 
3.2 Materials  
Ti-6Al-4V (composed of 90% titanium, 6% aluminum, and 4% vanadium) foil of 
a 0.52 mm thickness was purchased from Goodfellow, Inc. COOH-Pa (97%), NHS, EDC, 
D-penicillamine (98-101%), NaNO2 (99.999% trace metal), and Dulbecco’s PBS 
(pH=7.4) were purchased from Sigma-Aldrich and used as received. DTPA (>99.0%) 
was purchased from Fluka. HCl and 2-propanol (Optima) were obtained from Fisher 
Scientific, and used as received. Tetrahydrofuran (THF, Optima) was obtained from 
Fisher Scientific and was distilled over sodium and benzophenone before use. Ethanol 
(200 proof) and deionized water (ddH2O) were obtained from Duquesne University. The 
nitrate/nitrite colorimetric assay kit was purchased from Cayman Chemical Company.  
LB Media was obtained from MP Biomedicals, Inc. and two capsules were 
dissolved per 50 mL of ddH2O and autoclaved before use. Tetracycline hydrochloride 
was obtained from Fisher Scientific. Ampicillin sodium salt was obtained from Sigma-
Aldrich. E. coli (ATCC® 25922), S. epidermidis (ATCC® 14990), 3T3 Swiss Albino 
mouse embryo fibroblasts (CCL-92) were obtained from ATCC. DMEM, FBS, 
penicillin/streptavidin, and Trypsin/EDTA were purchased from LONZA. The 
LIVE/DEAD® Cytotoxicity/Viability Assay Kit for mammalian cells was purchased 
from Life Technologies/Fisher Scientific.  
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3.3 Methods 
3.3.1 Ti-6Al-4V Preparation 
Ti-6Al-4V foils were sanded using four decreasing grain size sand papers (150, 
320, 400 and 600 grit) and then cut into 1 cm by 1 cm square coupons. The coupons were 
cleaned by sonication in acetone for 15-minutes, followed by immersion in boiling 
methanol for 15-minutes. This cleaning procedure removes impurities from 
manufacturing, organic material, and metallic dust from the surface of the metal coupons. 
The coupons were placed in a 60°C oven overnight to dry before further use. 
 
3.3.2 S-Nitroso-Penicillamine Immobilization onto Ti-6Al-4V 
S-nitroso-penicillamine, a RSNO NO donor, was immobilized onto the surface of 
Ti-6Al-4V metal oxide alloy using a two-step approach (Scheme 3.1). Briefly, SAMs of 
COOH-Pa were formed on the oxide surface of Ti-6Al-4V, presenting a carboxylic acid 
group at the tail of the formed monolayer. Carbodiimide coupling was utilized to form an 
amide bond with the primary amine within the S-nitroso-penicillamine NO donor and the 
carboxylic acid functionality at the surface of the Ti-6Al-4V.   
 
 
 79 
 
(1) (2) 
 
Scheme 3.1: The two-step reaction sequence for the immobilization of S-nitroso-
penicillamine to the surface of COOH-Pa modified Ti-6Al-4V. The carboxylic acid group 
is first activated with EDC and NHS (1) and then reacted with S-nitroso-penicillamine to 
form an amide bond (2).  
 
3.3.2.1 Self-Assembled Monolayer Formation 
SAMs of COOH-Pa were formed on the surface of cleaned Ti-6Al-4V using an 
aerosol spray deposition method. A 1 mM solution of COOH-Pa was prepared in distilled 
THF and was poured into a thin layer chromatography (TLC) sprayer. The TLC sprayer 
was used in conjunction with a stream of nitrogen gas to spray the 1 mM COOH-Pa 
solution onto the Ti-6Al-4V coupons in four different cycles. Each coupon was sprayed 
once with COOH-Pa, placed in the 60°C oven for 30 minutes, and then sprayed again 
with COOH-Pa for a total of four cycles. The coupons were then placed in the oven at 
60°C overnight to remove excess solvent before film characterization. To test monolayer 
stability, the coupons were rinsed and sonicated in THF for 15 minutes to remove any 
physisorbed or weakly chemisorbed COOH-Pa molecules. 
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3.3.2.2 Activation of COOH-Pa Modified Ti-6Al-4V 
Coupons with stable COOH-Pa monolayers were immersed in a solution 
containing 20 mM EDC and 50 mM NHS in 2-propanol.10, 38 The reaction proceeded with 
nitrogen bubbling through the solution for 1.5 hours, protected from light. The coupons 
were removed from solution and dried under vacuum (0.1 Torr) for 45 minutes before 
further reaction.  
 
3.3.2.3 S-Nitroso-Penicillamine Immobilization to COOH-Pa Modified   
Ti-6Al-4V 
 
S-nitroso-penicillamine was generated by reacting D-penicillamine with acidified 
nitrite. Briefly, 100 mM of penicillamine was reacted with 100 mM NaNO2 and 250 mM 
HCl in the presence of 100 μM DTPA (a copper chelator) in an ice bath for 1 hour and 15 
minutes, while protected from light (Scheme 3.2).39, 40 
 
             
Scheme 3.2: The formation of S-nitroso-penicillamine from the reaction of acidified 
nitrite with penicillamine in the presence of a metal chelator.  
 
After RSNO formation, four mL of the S-nitroso-penicillamine solution was 
diluted with 6 mL of 200 proof ethanol. The activated COOH-Pa coupons were immersed 
in the ethanol solution for 1.5 hours, with nitrogen bubbling through. The coupons were 
removed from the solution without a solvent meniscus and placed under vacuum 
overnight to dry.  
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3.3.3 Characterization of Nitric Oxide Releasing Ti-6Al-4V 
3.3.3.1 Infrared Spectroscopy  
SAM formation and stability, as well as the activation and immobilization steps of 
S-nitroso-penicillamine on Ti-6Al-4V, was characterized using a Nexus 470 Fourier 
Transform Infrared (FTIR) spectrometer with a diffuse reflectance infrared Fourier 
transform (DRIFT) attachment. Infrared spectroscopy was used to analyze the alkyl chain 
ordering and binding modes of monolayers formed and functional groups present at the 
surface of Ti-6Al-4V after activation and functionalization of the surface. Each sample 
was analyzed under inert conditions with 256 scans (4000 to 400 cm-1) and a 4 cm-1 
resolution. Clean, unmodified Ti-6Al-4V was used as a background before sample 
collection.  
 
3.3.3.2 Ultraviolet-Visible Spectroscopy  
Liquid S-nitroso-penicillamine was scanned from 800 nm to 250 nm using a 
Varian UV-Vis spectrophotometer (Agilent Technologies, USA) to determine the 
wavelength of maximum absorbance and the purity of the formed RSNO compound. S-
nitroso-penicillamine was diluted 1:1 with ddH2O to reduce signal saturation. 
 
3.3.4 Nitric Oxide Release Quantitation from Modified Ti-6Al-4V 
 
NO release from S-nitroso-penicillamine modified Ti-6Al-4V was monitored over 
48 hours using the Griess assay.35, 41 Briefly, a three coupons of S-nitroso-penicillamine 
modified Ti-6Al-4V were added to three separate vials containing 900 μL of PBS and 
placed on an incubator/shaker at 37°C, while protected from light. The metal ions 
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contained in PBS begins the decomposition process of RSNOs so that the amount of NO 
released can be determined.42 At each time point, the PBS was collected and frozen at      
-20°C until assay preparation. The same volume of PBS that was removed at each time 
point was replaced.35  
The PBS samples were thawed and a 96-well plate was prepared per kit 
instructions. The assay included reagents that allowed for the construction of a 
nitrate/nitrite calibration curve. Briefly, 80 μL of thawed PBS sample was incubated with 
10 μL of enzyme cofactor mixture and 10 μL of nitrate reductase mixture. After a 1-hour 
incubation, 50 μL of Griess Reagent R1 and 50 μL of Griess Reagent R2 were added to 
each well. The well plate was incubated at room temperature for 10 minutes before being 
read using an Infinite M1000 microplate reader (Tecan, USA) at an absorbance of 540 
nm. The concentration of NO was determined by information obtained by the calibration 
curve and equation provided by Cayman Chemical (n=9).43  
 
3.3.5 Antimicrobial Effects of Nitric Oxide Releasing Ti-6Al-4V  
3.3.5.1 Escherichia coli and Staphylococcus epidermidis Culture  
3.3.5.1.1 Escherichia coli  
E. coli (ATCC® 25922) was frozen in vials of glycerol and stored at -80°C until 
use. To begin a culture, one full inoculation loop of E. coli was added to 10 mL of LB 
media in a T-25 cm2 culture flask. The E. coli flask was incubated overnight under 
shaking conditions at 37°C and diluted to an OD600nm of 0.1 before beginning bacterial 
assays.  
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3.3.5.1.2 Staphylococcus epidermidis  
S. epidermidis (ATCC® 14990) was frozen in vials of glycerol and stored at  
-80°C until use. To begin a culture, one full inoculation loop of S. epidermidis was added 
to 10 mL of LB media in a T-25 cm2 culture flask. LB media promoted slower growth of 
S. epidermidis and thus was used over TSB. The S. epidermidis was incubated overnight 
on a shaker at 37°C and diluted to an OD600nm of 0.1 before beginning bacterial assays. 
Experiments involving S. epidermidis required orbital shaking conditions at 230 RPM to 
prevent bacterial cell adhesion to the individual wells of the well plates. 
 
3.3.5.2 Bacterial Turbidity Assay with S-Nitroso-Penicillamine 
The antimicrobial effect of the unbound, S-nitroso-penicillamine donor was tested 
against both E. coli and S. epidermidis before testing NO release from the Ti-6Al-4V 
coupons.  In each well of a 24-well plate, 100 μL of diluted S-nitroso-penicillamine (final 
well concentration of 5 μM) or PBS and 900 μL of planktonic OD600nm E. coli or S. 
epidermidis culture was added. Three wells each contained: (i) E. coli/S. epidermidis + 
PBS and (ii) E. coli/S. epidermidis + S-nitroso-penicillamine. The plate was placed in a 
shaker incubator (230 rpm for S. epidermidis) at 37°C for 2.5 hours while protected from 
light. After incubation, the OD600nm was collected for each well using a Varian UV-Vis 
spectrophotometer with three replicates read per well (n=9). LB media containing PBS or 
S-nitroso-penicillamine was utilized as the blank. 
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3.3.5.3 Bacterial Turbidity Assay with Nitric Oxide Releasing Ti-6Al-4V 
Bacterial optical density was used to monitor the effectiveness of NO release from 
Ti-6Al-4V coupons against planktonic cultures of E. coli and S. epidermidis in LB media. 
In each well of a 24-well plate, 100 μL PBS and 900 μL of planktonic OD600nm E. coli or 
S. epidermidis culture was added. Three wells each contained: (i) E. coli/S. epidermidis, 
(ii) E. coli/S. epidermidis + unmodified Ti-6Al-4V, or (iii) E. coli/S. epidermidis + S-
nitroso-penicillamine modified Ti-6Al-4V. The plate was placed in a shaker incubator 
(230 rpm for S. epidermidis) at 37°C for 2.5 hours while protected from light. After 
incubation, the OD600nm was collected for each well using a Varian UV-Vis 
spectrophotometer with three replicates read per well (n=9). LB media containing PBS 
was utilized as the blank. 
 
3.3.5.4 Antibiotic Susceptibility Assay with Nitric Oxide Releasing  
Ti-6Al-4V  
 
3.3.5.4.1 Determination of Effective Antibiotic Concentration  
 
As previously mentioned, a synergistic effect of nanomolar concentrations of NO 
and an antibiotic against P. aeruginosa was observed by Barraud et al.44 Thus, the 
synergistic effect of NO release from S-nitroso-penicillamine modified Ti-6Al-4V was 
determined. 100 ng/mL tetracycline was found used to only slightly inhibit bacterial 
growth, and thus was used in the antibiotic susceptibility assay involving E. coli. 
Ampicillin, an antibiotic commonly prescribed for gram-positive bacterial 
infections, was tested for synergistic effects with S-nitroso-penicillamine modified Ti-
6Al-4V against S. epidermidis.45 To individual wells on a 24 well plate, concentrations of 
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0.4, 0.5, and 0.6 μg/mL of ampicillin was added to 900 μL of S. epidermidis to reach a 
final volume of 1000 μL with PBS (3 wells each). Concentrations greater than 1 μg/mL 
were completely inhibitory against S. epidermidis cultures. The plate was incubated at 
37°C under shaking conditions, and the OD600nm was determined after 2.5 hours on the 
using the Varian UV-Vis spectrophotometer. Each well was read in triplicate with LB 
and the concentration of antibiotic subtracted as blank (n=9). An antibiotic concentration 
that exhibits a bacteriostatic effect is needed for the antibiotic susceptibility assay.44  
 
3.3.5.4.2 Antibiotic Susceptibility of Nitric Oxide Releasing Ti-6Al-4V  
To each of three wells, 900 μL of planktonic E. coli or S. epidermidis culture was 
placed in each well of a 24-well plate, with: (i) E. coli/S. epidermidis + 100 μL PBS, (ii) 
E. coli/S. epidermidis + 100 μL tetracycline/ampicillin + unmodified Ti-6Al-4V or (iii) E. 
coli/S. epidermidis + 100 μL tetracycline/ampicillin + S-nitroso-penicillamine modified 
Ti-6Al-4V. The plate was incubated for 2.5 hours at 37°C under shaking conditions (230 
rpm for S. epidermidis experiments). The bacterial turbidity of each well was collected 
using the Varian UV-Vis spectrophotometer at 600 nm, with 3 replicates of each well and 
LB media with the antibiotic/PBS subtracted as the blank (n=9).   
 
3.3.6 Cytotoxicity of Nitric Oxide Releasing Ti-6Al-4V 
The cytotoxicity of S-nitroso-penicillamine modified Ti-6Al-4V was determined 
using 3T3 Swiss Albino mouse embryo fibroblasts. The cells were maintained in DMEM 
that was supplemented with 10% FBS and 1% penicillin/streptavidin. The fibroblasts 
were cultured until approximately 80% confluent. The cells were trypsinized from the 
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flask, counted, and were diluted to a concentration of 10,000 cells per mL of fresh 
DMEM. Three of each type of coupon, either unmodified or S-nitroso-penicillamine 
modified Ti-6Al-4V, was placed in a well of a 24 well plate and 1 mL of cell suspension 
was added. The plate was incubated for 24 hours at 37°C in a 5% carbon dioxide 
environment.  
After a 24 hour incubation, the number of live and dead fibroblast cells on the Ti-
6Al-4V surfaces was determined using a Live/Dead® Viability/Cytotoxicity Kit. Five 
spots on each microscope slide with an area of 0.6 mm2 were imaged under 10x 
magnification using fluorescence filters on an Axioskop2 with AxioVision software. The 
number of live and dead cells was counted on 45 images for each sample and control. 
The percent viability for each condition was calculated using Equation 2.1 and 
normalized to the fibroblast control.46  
 
3.3.7 Statistics  
Statistical analysis was performed using Origin 8.0 software. ANOVA with a 
Bonferroni post-hoc test was used to determine the averages and statistical significance of 
data at the p<0.05 level of significance, where applicable. Outliers were determined by 
the Grubb’s test and excluded from presented data. All statistically analyzed data is 
presented as mean ± standard error. 
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3.4 Results  
3.4.1 Characterization of S-Nitroso-Penicillamine Modified Ti-6Al-4V 
3.4.1.1 Self-Assembled Monolayer Formation on Ti-6Al-4V 
The surface of the Ti-6Al-4V metal oxide surface was reacted with COOH-Pa, a 
phosphonic acid, to deposit the organic SAM onto the surface of the metal. The addition 
of this organic acid presents a more reactive tail group, a carboxylic acid, at the metal 
surface.  
Methylene stretching peaks for an ordered monolayer are νCH2 asymmetic ≤ 2918 cm-1 
and νCH2 symmetic ≤ 2850 cm-1.25, 30, 31, 47 The methylene stretching region of the DRIFT 
spectrum of COOH-Pa on Ti-6Al-4V contains two peaks corresponding to the 
asymmetric and symmetric CH2 stretches, at 2917 and 2848 cm
-1, respectively (Figure 
3.3a). The peak positions are indicative of a well-ordered film on the metal surface, 
characterized by alkyl chains in an all trans, crystalline-like conformation.25, 31 
Additionally, the methylene stretches remain after solvent rinse and sonication, indicating 
a stable monolayer of COOH-Pa on the surface of Ti-6Al-4V.25  
When using organic acids containing termini of both carboxylic and phosphonic 
acid functional groups, the SAM preferentially forms with phosphonic acid as the head 
group and carboxylic acid group free at the tail.10, 25, 48 The binding mode of COOH-Pa to 
the Ti-6Al-4V surface was also examined using DRIFT (Figure 3.3b). The binding mode 
is determined by comparing solid COOH-Pa to that of the COOH-Pa monolayer on Ti-
6Al-4V.10 The solid COOH-Pa spectrum contains peaks at 1214, 1077, 1008, 951, and 
934 cm-1 corresponding to the vP=O, vP-O, asym, vP-O sym, vP-OH, and vP-OH of the phosphonic 
acid head group, respectively. The DRIFT spectrum of COOH-Pa bound to the Ti-6Al-
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4V surface contains one broad peak at 1085 cm-1 for vP-O, combined with the loss of both 
vP-OH peaks and the vP=O peak suggesting a tridentate binding mode. However, the slight 
shoulder off of the broad vP-O peak could suggests some hydrogen bonding between the 
oxygen atom of the P=O stretch and the hydrogen of a surface hydroxyl, indicating an 
overall mixture of bidentate and tridentate binding is likely occurring (Figure 3.3c).10  
          (c) 
Figure 3.3: DRIFT spectra of the methylene stretching region of COOH-Pa on the 
surface of Ti-6Al-4V indicates an ordered, stable SAM (a) and binding region, where the 
broad peak at 1085 cm-1 with a slight shoulder in the spectrum of the binding region of 
COOH-Pa (b) confirms a mixture of bidentate and tridentate binding (c). 
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3.4.1.2 Immobilization of S-Nitroso-Penicillamine to COOH-Pa Modified 
Ti-6Al-4V 
 
The immobilization of S-nitroso-penicillamine to the carboxylic acid tail of 
COOH-Pa was completed using carbodiimide coupling. S-nitroso-penicillamine contains 
both a carboxylic acid and amine functionality in the same molecule. To avoid undesired 
reactions with neighboring molecules, the attachment of S-nitroso-penicillamine was 
completed in a two-step process. The carboxylic acid tail on the surface of Ti-6Al-4V 
was first activated with EDC and reacted with NHS to form a more sufficient leaving 
group for amide bond formation. The formation of a succinimidyl ester at the carboxylic 
acid tail indicates successful leaving group formation. The following peaks confirm the 
attachment of NHS to the carboxylic acid tail of COOH-Pa: 1813 cm-1 for νC=O for the 
NHS ester, 1781 cm-1 for νC=O for the symmetric stretch of the succinimidyl ester within 
the ring, and 1740 cm-1 νC=O for the asymmetric stretch of the succinimidyl ester within 
the ring (Figure 3.4).49 The stretch at 1210 cm-1 is that of νC-O of the ester group.49 
Incomplete activation of the COOH-Pa carboxylic acid tails at the surface can be 
observed by the peak at 1722 cm-1 for νC=O.49 Additionally, the stretch at 1556 cm-1 is that 
of a formed unreactive side product, N-acylurea.49 The formation of this product is 
difficult to prevent under ambient conditions, and thus is ultimately a product in every 
carbodiimide coupling reaction.49 After this activation step, the phosphonic acid head 
group remains bound the surface in a primarily tridentate manner, based on the P-O 
stretch at 1075 cm-1. 
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Figure 3.4: EDC and NHS activation of carboxylic acid groups presented at the surface 
of  the COOH-Pa monolayer on Ti-6Al-4V. Stretches for ester formation at 1813 cm-1, 
1781 cm-1, and 1740 cm-1 indicated successful activation of the tail group for further 
amide bond formation.  
 
 
UV-Vis spectroscopy was used to confirm the successful synthesis of S-nitroso-
penicillamine. Absorbance maxima at 340 nm and 595 nm are indicative of the electronic 
transitions of π →  π* and nN →  π*, respectively, for the SNO functionality in pure, 
unbound S-nitroso-penicillamine (Figure 3.5).50-52 Confirmation of this pure synthesis 
allows for further reaction, while the lack of the nitrite and nitrous acid signatures from 
the NO donor indicates that no excess nitrite or nitrous acid was present in the samples, 
crucial for the success of the NO release assay and the system itself.  
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Figure 3.5: UV-Visible spectrum of the unbound S-nitroso-penicillamine liquid NO 
donor. The wavelength of maximum absorbance at 342 nm and secondary absorbance at 
595 nm confirms successful RSNO formation. 
 
The attachment of S-nitroso-penicillamine to the surface was completed through 
the formation of an amide bond. This bond was formed by reacting EDC/NHS activated 
Ti-6Al-4V with a solution of the NO donor in ethanol. The attachment of S-nitroso-
penicillamine was confirmed by the presence of the νC=O amide I stretch at 1648 cm-1 and 
the νN-H amide II stretch at 1575 cm-1 (Figure 3.6). The peak at 1730 cm-1 is that of free 
carboxylic acid present in the S-nitroso-penicillamine NO donor, while the stretch at 
1510 cm-1 for νN=O indicates that there is NO on the surface of Ti-6Al-4V. The methylene 
stretching peaks at 2913 cm-1 and 2847 cm-1 indicate that the COOH-Pa SAM is still 
adhered to the Ti-6Al-4V metal oxide surface. 
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Figure 3.6: DRIFT spectrum of the attachment of S-nitroso-penicillamine to the COOH-
PA modified Ti-6Al-4V surface as confirmed by the presence of amide I (1648 cm-1) and 
amide II (1575 cm-1).  The NO group is present at 1510 cm-1 and the stretch at 1730 cm-1 
indicates free carboxylic acid from the S-nitroso-penicillamine donor. 
 
3.4.2 Nitric Oxide Release from S-Nitroso-Penicillamine Modified        
Ti-6Al-4V 
 
The total amount of NO released from the surface of NO modified Ti-6Al-4V was 
determined using a nitrate/nitrite colorimetric (Griess) assay. Since NO degrades rapidly 
into nitrate under physiological conditions, this assay converts nitrates to nitrites, and the 
total amount of nitrite is quantified to reflect the amount of NO released.35 The total 
amount of NO released by S-nitroso-penicillamine modified Ti-6Al-4V cumulatively 
over a 48-hour time period was 89.6 ± 4.8 nmol/cm2 (Figure 3.7). The NO was burst 
released between the first and second hour of the assay, followed by a slow release of NO 
for the remainder of the assay. The maximum amount of NO released, 77.0 ± 4.8 
nmol/cm2, occurred at the two-hour time point. 
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Figure 3.7: Quantitation of NO release from S-nitroso-penicillamine modified Ti-6Al-
4V, determined using the Griess assay. The modified Ti-6Al-4V coupons released 89.6 ± 
4.8 nmol NO/cm2 over a 48-hour time period. Each data point expresses the average NO 
release ± standard error (n=9). 
 
 
3.4.3 Antimicrobial Effects of S-Nitroso-Penicillamine Modified  
Ti-6Al-4V 
 
3.4.3.1 Antimicrobial Effects of S-Nitroso-Penicillamine  
 
The antimicrobial effect of the unbound, S-nitroso-penicillamine donor was tested 
against both E. coli and S. epidermidis via bacterial turbidity. After incubating 0.1 
OD600nm E. coli culture with unbound S-nitroso-penicillamine for 2.5 hours, the OD600nm 
was collected for the E. coli control and sample. The normalized average OD600nm was 
1.00 ± 0.002 for the E. coli control and 0.161 ± 4.0 x 10-4 for E. coli treated with S-
nitroso-penicillamine, resulting in a 83.9 ± 0.05 % inhibition of E. coli growth (Figure 
3.8a).  
The unbound S-nitroso-penicillamine NO donor was also tested against 
planktonic S. epidermidis culture. After 2.5 hours of growth, the normalized average 
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OD600nm was 1.00 ± 0.025 for the S. epidermidis control and 0.283 ± 0.005 for S. 
epidermidis treated with S-nitroso-penicillamine, resulting in a 71.6 ± 0.82 % inhibition 
of S. epidermidis growth (Figure 3.8b). These results indicate that S-nitroso-penicillamine 
is active against both E. coli and S. epidermidis planktonic cultures.  
 
Figure 3.8: Bacterial turbidity assay of E. coli (a) and S. epidermidis (b) cultures treated 
with unbound S-nitroso-penicillamine, shown as mean ± standard error, p<0.05. E. coli 
and S-nitroso-penicillamine treated E. coli were statistically different (*). S. epidermidis 
and S-nitroso-penicillamine treated S. epidermidis were statistically different (*).  
 
 
3.4.3.2 Bacterial Turbidity Tests with S-Nitroso-Penicillamine Modified 
Ti-6Al-4V  
 
3.4.3.2.1 Escherichia coli  
The antibacterial activity of S-nitroso-penicillamine modified Ti-6Al-4V was 
assessed by a bacterial turbidity E. coli challenge, where the planktonic growth of E. coli 
incubated with Ti-6Al-4V coupons was monitored. The ability of the S-nitroso-
penicillamine NO donor to retain it’s antimicrobial ability after covalent attachment to 
the COOH-Pa thin film is important for localized, site specific treatment.16 After 
incubating a 0.1 OD600nm E. coli culture with Ti-6Al-4V coupons for 2.5 hours, the 
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OD600nm was collected for all E. coli controls and samples. The normalized average 
OD600nm was 1.00 ± 0.002 for the E. coli control, 0.989 ± 0.007 for the unmodified Ti-
6Al-4V control, and 0.585 ± 0.011 for S-nitroso-penicillamine modified Ti-6Al-4V 
(Figure 3.9). The OD600nm of the E. coli incubated with S-nitroso-penicillamine modified 
Ti-6Al-4V was statistically lower than both the E. coli control and E. coli grown with 
unmodified Ti-6Al-4V coupons. E. coli growth in the presence of S-nitroso-penicillamine 
modified substrates resulted in a 41.5 ± 1.2 % growth reduction compared to the E. coli 
control. This confirms that S-nitroso-penicillamine is an active antimicrobial compound 
after being immobilized to the Ti-6Al-4V metal oxide surface. Additionally, E. coli 
grown with and without Ti-Al-4V coupons were statistically the same, indicating that E. 
coli cells are not adhering to the surface of the Ti-6Al-4V coupons.  
             
Figure 3.9: Bacterial turbidity assay of E. coli cultures treated with S-nitroso-
penicillamine modified Ti-6Al-4V shown as mean ± standard error, p<0.05. E. coli and 
E. coli grown with unmodified Ti-6Al-4V substrates were not statistically different (#). 
E. coli inhibition by S-nitroso-penicillamine modified Ti-6Al-4V is statistically different 
(*) than all other groups. 
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3.4.3.2.2 Staphylococcus epidermidis 
The planktonic growth of S. epidermidis after incubation with S-nitroso-
penicillamine modified Ti-6Al-4V coupons was monitored by a bacterial turbidity 
challenge. After incubating a 0.1 OD600nm S. epidermidis culture with Ti-6Al-4V coupons 
for 2.5 hours, the OD600nm was collected for all S. epidermidis controls and NO modified 
Ti-6Al-4V samples. The average OD600nm was 1.00 ± 0.005 for the S. epidermidis 
control, 0.985 ± 0.006 for the unmodified Ti-6Al-4V control, and 0.747 ± 0.005 for S-
nitroso-penicillamine modified Ti-6Al-4V (Figure 3.10). The OD600nm of the S. 
epidermidis incubated with S-nitroso-penicillamine modified Ti-6Al-4V substrates was 
statistically lower than both the S. epidermidis control and S. epidermidis grown with 
unmodified Ti-6Al-4V. S. epidermidis growth in the presence of S-nitroso-penicillamine 
modified Ti-6Al-4V resulted in a 25.3 ± 0.6 % growth reduction compared to the S. 
epidermidis control. The higher shaking speeds for S. epidermidis growth reduced 
bacterial adhesion to the surface of Ti-6Al-4V, as the OD600nm of S. epidermidis and S. 
epidermidis grown with unmodified Ti-6Al-4V were statistically the same.  
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Figure 3.10: Bacterial turbidity assay of S. epidermidis cultures grown with S-nitroso-
penicillamine modified Ti-6Al-4V, shown as mean ± standard error, p<0.05. S. 
epidermidis and S. epidermidis grown with unmodified Ti-6Al-4V substrates were not 
statistically different (#). S. epidermidis inhibition by S-nitroso-penicillamine modified 
Ti-6Al-4V is statistically different (*) than all other groups. 
 
3.4.3.3 Antibiotic Susceptibility of S-Nitroso-Penicillamine Modified  
Ti-6Al-4V  
 
3.4.3.3.1 Escherichia coli 
The synergistic effect of S-nitroso-penicillamine modified Ti-6Al-4V was tested 
with tetracycline against E. coli planktonic cultures. After 2.5 hours, the normalized 
average OD600nm for E. coli grown without tetracycline was 1.00 ± 0.002, E. coli grown 
with 100 ng/mL tetracycline and unmodified Ti-6Al-4V had an OD600nm of 0.541 ± 
0.001, and the average OD600nm for E. coli cultures in the presence of S-nitroso-
penicillamine modified Ti-6Al-4V and tetracycline was 0.349 ± 0.007 (Figure 3.11). The 
OD600nm of E. coli incubated with S-nitroso-penicillamine modified Ti-6Al-4V and 
tetracycline was statistically lower than the E. coli control and E. coli treated with 
tetracycline, indicating successful growth reduction. The addition of S-nitroso-
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penicillamine Ti-6Al-4V to an antibiotic increases the effectiveness of tetracycline by 
35.4 ± 1.3 %, and thus a synergistic effect was observed. 
                        
 
Figure 3.11: Antibiotic susceptibility challenge in the presence of E. coli cultures treated 
with 100 ng/mL tetracycline and S-nitroso-penicillamine modified Ti-6Al-4V, shown as 
mean ± standard error, p<0.05. E. coli treated with S-nitroso-penicillamine modified Ti-
6Al-4V and tetracycline is statistically different (*) than all other groups. 
 
3.4.3.3.2 Staphylococcus epidermidis 
As the NO released from S-nitroso-penicillamine modified Ti-6Al-4V increased 
the effectiveness of tetracycline, the same effect was tested with S. epidermidis in the 
presence of ampicillin. The concentration of ampicillin used was 0.4 μg/mL, as 
determined by testing various concentrations of ampicillin against S. epidermidis (Figure 
3.12). This concentration reduced bacterial growth slightly but is not considered fully 
inhibitory against S. epidermidis.44 
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Figure 3.12: Concentrations of ampicillin tested against S. epidermidis to determine an 
appropriate concentration to test for a synergistic effect with S-nitroso-penicillamine 
modified Ti-6Al-4V. The desired concentration should be slightly inhibitory as to still 
promote the growth of S. epidermidis, and thus 0.4 μg/mL was chosen.  
 
 
After 2.5 hours, the normalized average OD600nm for S. epidermidis without 
ampicillin was 1.00 ± 5.0 x 10-4. S. epidermidis grown with 0.4 μg/mL ampicillin and 
unmodified Ti-6Al-4V had an OD600nm of 0.542 ± 0.01 and the average OD600nm for S. 
epidermidis grown with S-nitroso-penicillamine modified Ti-6Al-4V and ampicillin was 
0.559 ± 0.003 (Figure 3.13). The OD600nm of S. epidermidis incubated with S-nitroso-
penicillamine modified Ti-6Al-4V and ampicillin was not statistically different than S. 
epidermidis cultures grown with unmodified Ti-6Al-4V and ampicillin, indicating no 
synergistic effect against a gram-positive bacteria species. 
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Figure 3.13: Antibiotic susceptibility challenge of S. epidermidis cultures treated with 
0.4 μg/mL ampicillin and S-nitroso-penicillamine modified Ti-6Al-4V, shown as mean ± 
standard error, p<0.05. S. epidermidis grown with S-nitroso-penicillamine modified Ti-
6Al-4V and ampicillin and S. epidermidis grown with unmodified Ti-6Al-4V and 
ampicillin were not statistically different (#), indicating no synergistic effect. 
 
 
3.4.4 Cytotoxic Effects of S-Nitroso-Penicillamine Modified Ti-6Al-4V  
The cell viability of NIH3T3 fibroblasts grown on S-nitroso-penicillamine 
modified Ti-6Al-4V was determined using the Live/Dead® Viability/Cytotoxicity Assay. 
Live and dead cells were counted on each microscope image and the average percent 
viability was calculated.46 The resulting data was normalized to the fibroblasts grown on 
unmodified Ti-6Al-4V. The normalized average percent cell viability for fibroblasts 
grown on unmodified Ti-6Al-4V and S-nitroso-penicillamine modified Ti-6Al-4V was 
100.0 ± 1.3 % and 101.9 ± 1.6 %, respectively (Figure 3.14). Fibroblasts grown on S-
nitroso-penicillamine modified Ti-6Al-4V had statistically the same percent cell viability 
as the unmodified Ti-6Al-4V control, indicating that functionalization of the surface to 
release NO did not cause the Ti-6Al-4V substrates to be cytotoxic to mammalian cells.   
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Figure 3.14: Normalized average percent cell viability of NIH3T3 mouse embryo 
fibroblasts grown on unmodified Ti-6Al-4V and S-nitroso-penicillamine modified Ti-
6Al-4V. Data is shown as mean ± standard error, p<0.05. Fibroblast growth was not 
statistically different between Ti-6Al-4V and NO releasing Ti-6Al-4V (#). The 
Live/Dead images of NIH3T3 fibroblasts are below, from left to right: fibroblasts grown 
on unmodified Ti-6Al-4V and fibroblasts grown on S-nitroso-penicillamine modified Ti-
6Al-4V. 
 
3.5 Discussion  
NO releasing compounds have not been previously covalently immobilized onto 
the surface of metal oxide implant materials but have been incorporated into polymeric 
matrices on the metal surface.35-37 Most publications involving NO release from 
biomaterials, whether metallic, silicate, or polymeric, utilize potentially carcinogenic 
NONOate chemistry.35-37, 53-58 Here, the release of NO from a covalently immobilized 
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RSNO donor from the surface of Ti-6Al-4V to reduce E. coli and S. epidermidis growth 
and increase the effectiveness of an antibiotic was investigated. This approach has the 
potential to be utilized in implant materials to reduce the colonization of bacteria post-
implantation, and ultimately prevent implant rejection.  
The surface of Ti-6Al-4V was first modified with a COOH-Pa SAM. The 
phosphonic acid functional group of the organic acid was bound to the surface of Ti-6Al-
4V using the thin oxide layer present on the metal surface, acting as the head group of the 
SAM. The methylene stretches of the alkyl chain in the DRIFT spectrum indicate that the 
alkyl chain is ordered, and in the optimal, crystalline packing orientation on the surface. 
This monolayer was also stable to rinsing and sonication in solvent, which are tests for 
mechanical and chemical stability. COOH-Pa was bound to the surface in a mixture of 
bidentate and tridentate binding, as seen by a broad stretch at 1085 cm-1 in the DRIFT 
spectrum with a shoulder indicating possible hydrogen bonding with the P=O of the head 
group with the oxide surface.10  
The COOH-Pa was bound to the surface using the phosphonic head group, and 
thus the carboxylic acid tail groups are presented via the ordered alkyl chain at the 
interface for future reactions. This interfacial presentation makes carboxylic acid 
available for carbodiimide coupling with the primary amine functionality within the 
RSNO donor, S-nitroso-penicillamine, to form an amide bond. Since S-nitroso-
penicillamine contains both a primary amine and carboxylic acid functionality, the 
COOH-Pa modified Ti-6Al-4V required EDC/NHS activation before reacting with the S-
nitroso-penicillamine NO donor. Completing the coupling reaction in a single mixture 
likely would have caused amide bond formation between individual S-nitroso-
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penicillamine molecules, and not to the surface carboxylic acid groups presented from the 
surface.  The tail of the COOH-Pa SAM was activated with EDC and NHS to present 
NHS at the surface as a more effective leaving group during amide bond formation. 
Activation was confirmed by the presence of stretches in the infrared spectrum 
characteristic of succinimidyl ester formation.  
S-nitroso-penicillamine was synthesized by reacting penicillamine with acidified 
nitrite. The synthesis of the RSNO donor was confirmed using UV-Vis, where the 
wavelength of maximum absorbance at 340 nm matches that of the characteristic SNO 
group of RSNO donors.51, 52, 59 The UV-Vis spectrum of unbound S-nitroso-penicillamine 
lacks contributions from excess nitrite and nitrous acid from the synthesis step, and thus 
could be utilized in further reactions and NO release assays.60  
Reaction of the EDC/NHS activated COOH-Pa modified Ti-6Al-4V coupons with 
S-nitroso-penicillamine showed two stretches indicative of amide I and amide II bond 
formation in the infrared spectra, indicating successful S-nitroso-penicillamine 
attachment to the surface. Additionally, the NO moiety and the unreacted carboxylic acid 
group of S-nitroso-penicillamine appearing in the infrared spectrum further confirm 
attachment to the metal oxide surface.  
The amount of NO released from the surface of S-nitroso-penicillamine modified 
Ti-6Al-4V was determined through the Griess Assay, which measures the amount of NO 
as it is converted from nitrate to nitrite. From this assay, it was determined that 89.6 ± 4.8 
nmol of NO was released per cm2. This amount of NO is less than the μM levels of NO 
reported by Gallo et al.,35  but more than the pmole/cm2s amounts reported by Nablo et 
al.37 and Holt et al.36 S-nitroso-penicillamine is a tertiary NO donor, which is the most 
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stable of the RSNO donors, and is likely responsible for the slow, increasing release of 
NO over the 48 time period.  
Unbound S-nitroso-penicillamine was found to exhibit inhibitory effects against 
both E. coli and S. epidermidis. To generate an antimicrobial surface, S-nitroso-
penicillamine should maintain its antimicrobial activity like the original, unbound 
molecule once immobilized. The nanomolar amount of NO released from S-nitroso-
penicillamine modified Ti-6Al-4V has a bacteriostatic effect against E. coli and S. 
epidermidis cultures, as observed from the bacterial turbidity assay. E. coli growth was 
inhibited by 41.5 ± 1.2 % when grown in the presence of S-nitroso-penicillamine 
modified Ti-6Al-4V, which is significantly different than the E. coli controls (p<0.05) 
(Figure 3.9). S-nitroso-penicillamine modified Ti-6Al-4V inhibited S. epidermidis growth 
by 25.3 ± 0.6 %, which is significantly different from the other S. epidermidis controls 
(p<0.05) (Figure 3.10). S-nitroso-penicillamine is not as bacteriostatic against S. 
epidermidis as compared to E. coli, but gram-positive bacteria in general are more 
difficult to inhibit with NO.61  
A synergistic effect of S-nitroso-penicillamine modified Ti-6Al-4V against E. coli 
when coupled with 100 ng/mL tetracycline resulted in a 35.4 ± 1.3 % reduction in growth 
when compared to E. coli cultures treated only with tetracycline (p<0.05) (Figure 3.11). 
NO is thought to change the physiology of bacterial cells, making them more susceptible 
to antibiotics.44 Low concentrations of NO are believed to induce a physiological 
transition, where NO converts a stationary phase cell into a more metabolically active 
cell.44 Antibiotics target these actively dividing cells, decreasing the population of cells in 
a culture, as seen by a decrease in optical density.44    
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The NO releasing metal oxide developed here is capable of increasing the 
effectiveness of an antibiotic, thus less antibiotic would be needed to treat a bacterial 
infection and subsequently reduce the risk of antibiotic resistance.  
Unfortunately, S-nitroso-penicillamine modified Ti-6Al-4V when coupled with 
ampicillin or vancomycin (data not shown) did not exhibit a synergistic effect against S. 
epidermidis (Figure 3.13). Gram-positive bacteria produce their own nM amounts of NO 
through bacterial NOS as a defense mechanism to oxidative stress, antimicrobial 
treatments, and other bacterial species.61 NO production in a gram-positive bacterial 
culture increases as the cells are treated with an antibiotic.61 Thus, the endogenously 
delivered nM amounts of NO in the presence of ampicillin does not inhibit bacterial 
growth because the bacteria within the culture are already making their own NO.61 
To consider this RSNO modified Ti-6Al-4V as a metallic implant material, the 
metal surface cannot be cytotoxic to mammalian cells in vitro. Though S-nitroso-
penicillamine modified Ti-6Al-4V inhibits bacterial cells, the coupons should not inhibit 
NIH3T3 fibroblast growth. S-nitroso-penicillamine modified Ti-6Al-4V showed no 
cytotoxic effect to fibroblasts after 24 hours, as the percent viability of fibroblasts grown 
on S-nitroso-penicillamine modified Ti-6Al-4V and unmodified Ti-6Al-4V were 
statistically the same (p<0.05). 
 
3.6 Conclusions 
A RSNO donor was immobilized at the surface of a Ti-6Al-4V metal oxide 
implant material using SAMs and carbodiimide coupling. The thin oxide layer on the 
surface of Ti-6Al-4V was reacted with organic acid to form a functional monolayer on 
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the metal oxide surface. The organic acid presented a carboxylic acid functional group at 
the interface, facilitating amide bond formation between the primary amine of S-nitroso-
penicillamine (Figure 3.15).  
 
                               
 
Figure 3.15: The surface of Ti-6Al-4V metal oxide alloy was modified with a 
phosphonic acid SAM and then functionalized at interface to immobilize S-nitroso-
penicillamine, a RSNO donor.  
 
 
The RSNO modified Ti-6Al-4V released nM amounts of NO in vitro and were 
bacteriostatic against E. coli and S. epidermidis cultures, indicating that the antimicrobial 
activity of S-nitroso-penicillamine remained after immobilization to the Ti-6Al-4V 
surface. S-nitroso-penicillamine modified Ti-6Al-4V increased the effectiveness of 
tetracycline against E. coli. However, a similar synergistic effect in conjunction with 
ampicillin against S. epidermidis was not observed. This may be because Staphylococci 
species are capable of producing their own NO when treated with antibiotic. The RSNO 
modified Ti-6Al-4V was non-cytotoxic to mammalian cells and thus offers the potential 
deliver NO directly to an implant infection site while reducing the amount of antibiotic 
needed, limiting the possibility of antibiotic resistance. 
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Chapter 4: Conclusions 
4.1 Nitric Oxide Delivery From Nanoparticles 
Nanoparticles have the ability to deliver drugs and small molecules to a specific 
site of infection through inhalation or injection. Unfortunately, a majority of the 
developed NO releasing nanoparticles are composed primarily of silica and silica 
derivatives. Silica nanoparticles are not approved for use by the FDA and can cause 
airway inflammation when inhaled.1, 2 The formulation of biodegradable and 
biocompatible nanoparticles composed of PLGA/PVA and RSNOs offer an attractive 
alternative for delivery of NO to the lung to combat biofilm infections in a patient with 
CF.  
 
4.1.1 S-Nitrosocysteamine Modified Nanoparticles 
PLGA nanoparticles, with PVA as the surfactant, were synthesized using a o/w 
emulsion technique that presented free hydroxyl groups at the nanoparticle surface. The 
hydroxyl groups at the interface of the nanoparticle were reacted with an COOH-Pa, an 
organic acid containing both phosphonic and carboxylic acid termini, to form a functional 
thin film at the surface. COOH-Pa presented a reactive free carboxylic acid group at the 
surface, and was utilized to attach SNC, a RSNO donor, to the exterior of the 
nanoparticle. Attachment of SNC to the nanoparticle surface resulted in the release of 
37.1 ± 1.1 nmol of NO per mg of nanoparticles under physiological conditions.  
The nM amount of NO released from the PLGA/PVA nanoparticles was tested 
against bacterial cultures of E. coli. When incubated with E. coli, the SNC modified 
nanoparticles inhibited bacterial growth by 31.8 ± 0.7 %, indicating a bacteriostatic effect 
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against planktonic cultures. The low concentration of NO released by SNC modified 
nanoparticles also exhibited a synergistic effect with a commonly prescribed gram-
negative antibiotic, tetracycline. The effectiveness of a ng/mL concentration of 
tetracycline when combined with the NO releasing nanoparticles was increased by 87.8 ± 
3.3 %. The combination of these NO releasing nanoparticles and an antibiotic provides an 
alternative to high doses of antibiotics; here, a low concentration of antibiotic was 
combined with a low concentration of NO to inhibit bacterial growth. The use of lower 
concentrations of antibiotics can reduce the emergence of antibiotic resistance.3  
Unfortunately, this synergistic effect was not observed with SNC modified 
nanoparticles and vancomycin against S. epidermidis cultures. Staphylococci species 
produce nM amounts of NO through bacterial NOS, and increase NO production when 
exposed to oxidative stress, antibiotics, or other bacterial species.4 The exogenous nM 
amounts of NO delivered by the SNC nanoparticles were ineffective, as the S. 
epidermidis increased their own NO production after being treated with an antibiotic.  
The morphology of the nanoparticles did not change after surface reactions, as 
confirmed by SEM, and the size of the particles remains at a size that could be suitable 
for drug delivery into the human body, including the lungs.5, 6 Nanoparticle size could be 
decreased during nanoparticle synthesis by varying concentrations of PLGA or PVA and 
by increasing homogenization times/speeds.7 Additionally, the SNC modified 
nanoparticles were non-cytotoxic to fibroblast mammalian cells. The nanoparticle size 
and non-toxicity make the SNC modified nanoparticles developed here suitable for 
inhaled delivery of NO to a CF lung to reduce bacterial infection and systemic antibiotic 
usage.  
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4.1.2 S-Nitroso-Penicillamine Modified Nanoparticles  
S-nitroso-penicillamine modified nanoparticles were not characterized to the 
extent of SNC modified nanoparticles, but served as proof of concept for the attachment 
of other RSNO donors to the surface of PLGA/PVA nanoparticles. The immobilization of 
S-nitroso-penicillamine required a two step attachment process, where the COOH-Pa 
carboxylic acid tail was first activated with EDC/NHS and then reacted with the S-
nitroso-penicillamine donor. The attachment of S-nitroso-penicillamine via amide bond 
formation was confirmed in the DRIFT spectrum. Additionally, the wavelength of 
maximum absorbance for the S-nitroso-penicillamine modified nanoparticles in the UV-
Vis spectrum matched that of the unbound S-nitroso-penicillamine donor, confirming 
attachment. A higher concentration of nanoparticles was required to confirm attachment 
via UV-Vis, indicating less NO at the nanoparticle surface compared to the SNC 
modified nanoparticles.  
The S-nitroso-penicillamine modified nanoparticles when incubated with E. coli 
planktonic cultures inhibited bacterial growth by 13.3 ± 2.6%, which is significantly less 
than the E. coli inhibition of SNC modified nanoparticles. S-nitroso-penicillamine 
modified nanoparticles when combined with tetracycline and E. coli, increased antibiotic 
effectiveness by 13.2 ± 1.5 %, indicating a minimal synergistic effect. This further 
confirmed that less NO was present at the surface of S-nitroso-penicillamine modified 
nanoparticles.  
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4.2 Nitric Oxide Delivery From a Metallic Implant Material  
As the number of total joint replacements increase in the United States, the 
incidences of implant infections continues to rise. As previously mentioned, almost 90% 
of all implanted materials show adhesion of pathogenic microorganisms on the surface 
prior to implantation.8 Therefore, inhibiting initial bacterial adhesion through anti-
infective implant materials would be essential to preventing implant failure and 
rejection.9 Antibiotics10-13 and antimicrobial peptides14, 15 have previously been presented 
at the surface of metal and ceramic biomaterials using SAMs to reduce bacterial adhesion 
and eventual biofilm formation. The use of SAMs to immobilize antimicrobial 
compounds chemically alters the outermost layer of the metallic biomaterial, but 
preserves the physical properties of the metallic implant.16 
 Ti-6Al-4V, a metallic implant material utilized commonly in hip and knee joint 
replacements, was modified at the surface to release NO from a RSNO.9 The thin oxide 
layer that forms spontaneously when exposed to oxygen and water was utilized to form a 
COOH-Pa SAM at the metal surface.17, 18 A stable, strongly bound, ordered monolayer 
was formed on the surface of Ti-6Al-4V via the phosphonic acid head group, leaving the 
carboxylic acid group at the interface for further functionalization. Like the attachment of 
S-nitroso-penicillamine to the surface of PLGA/PVA nanoparticles, a two step reaction 
process was required to prevent intermolecular amide bond formation. The 
immobilization of S-nitroso-penicillamine to the COOH-Pa modified Ti-6Al-4V 
proceeded after initial activation of the carboxylic acid tail with EDC and NHS. Amide 
bond formation was confirmed using DRIFT spectroscopy, based on the appearance of 
amide I, amide II, and NO stretches. The surface of S-nitroso-penicillamine modified Ti-
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6Al-4V released 89.6 ± 4.8 nmole of NO per cm2. These modified Ti-6Al-4V coupons 
did not reduce fibroblast adhesion or growth at the surface, indicating that this implant 
material could be potentially utilized in vivo.  
 Unbound S-nitroso-penicillamine was inhibitory against both E. coli and S. 
epidermidis cultures at the µM level. Immobilization of S-nitroso-penicillamine to the 
surface of Ti-6Al-4V should not change the antimicrobial activity of this donor. 
Nanomolar concentrations of NO released from the surface of Ti-6Al-4V were 
bacteriostatic against E. coli and S. epidermidis, inhibiting growth by 41.5 ± 1.2 % and 
25.3 ± 0.6 %, respectively. Thus, the antimicrobial activity of the S-nitroso-penicillamine 
donor remained after immobilization. The low concentrations of NO released from the 
surface of S-nitroso-penicillamine modified Ti-6Al-4V also increased the effectiveness of 
100 ng/mL tetracycline against E. coli by 35.4 ± 1.3 %, indicating a synergistic effect. 
Unfortunately, as with the SNC modified nanoparticles, the S-nitroso-penicillamine 
modified Ti-6Al-4V coupons in conjunction with a low dose of ampicillin did not exhibit 
a synergistic effect.   The combination of the developed NO releasing Ti-6Al-4V implant 
material with antibiotic provides an alterative to the systemic doses of antibiotics that are 
pre-operatively required, reducing harmful side effects and the potential for bacterial 
resistance.19 
 
4.3 Future Work 
4.3.1 Antibiotic Susceptibility  
Both the SNC modified nanoparticles and S-nitroso-penicillamine modified T-
6Al-4V did not increase the effectiveness of vancomycin or ampicillin against S. 
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epidermidis cultures. These antibiotics are beta lactam antibiotics that are 
biosynthetically produced by bacterial species, and can be produced within a mixed 
bacterial culture to eliminate other competitive bacterial species.20 The toxicity of these 
antibiotics occurs by promoting the formation of reactive oxygen and nitrogen species 
within and around the bacterial cell.4, 20 Thus, the delivery of exogenous NO goes 
unnoticed in combination with these reactive species generating antibiotics and gram-
positive bacteria that themselves produce NO. 
 The addition of an antimicrobial compound not derived from bacterial species 
delivered in conjunction with exogenous NO may exhibit a synergistic effect. Barraud et 
al. observed an increase in biofilm and planktonic P. aeruginosa inhibition by a 
detergent, sodium dodecyl sulfate (SDS), when combined with nM amounts of SNP.21 
SDS is a detergent that triggers cell lysis through the disruption or destruction of the 
outer cell membrane of bacterial cell (Figure 4.1a).22 Additionally, the ionic nature of 
SDS has a high affinity to bind to proteins and denature them.22 A combination of 
lysozyme and SDS could prove affective against S. epidermidis cultures, as lysozyme 
first hydrolyzes the β(1→4) linkages in the thick peptidoglycan layer of the gram-positive 
bacterial cell (Figure 4.1b).22, 23 The mode of action of detergents and enzymes do not 
include the formation of reactive nitrogen and oxygen species, and thus may exhibit a 
synergistic effect with NO against gram-positive bacteria. 
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Figure 4.1: (a) Mode of action for SDS and (b) lysozyme against bacterial cells.24  
 
4.3.2 Dual Surface Functionalization 
Biomaterials developed previously have been dual functionalized to release 
multiple bioactive compounds. Palchesko et al. immobilized a cell adhesion peptide and 
an antibiotic to create a biomaterial that could promote osseointegration while inhibiting 
S. aureus bacterial adhesion during and after implantation.12 Kruszewski et al. dual 
functionalized a stainless steel 316L metal oxide implant material to release two 
antibiotics, gentamicin and vancomycin, to reduce S. aureus biofilm formation on the 
surface.10 Both publications proved that each bioactive molecule was active after 
immobilization before dual functionalizing the surface.10, 12 
Here, the nanoparticle and Ti-6Al-4V surface could be dual functionalized with 
another bioactive molecule, such as an antibiotic, mucolytic agent, or cell adhesion 
peptide (Figure 4.2).  
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Figure 4.2: The surface of the PLGA/PVA or Ti-6Al-4V surface can be modified to 
release NO in conjunction with an antibiotic/antimicrobial peptide (a), a mucolytic agent 
(b), or a cell adhesion peptide (c) to form a dual functionalized material.  
 
The immobilization of an antibiotic in conjunction with NO could promote a 
synergistic effect, as observed with both surfaces in this work. Here, the nanoparticle or 
Ti-6Al-4V surface would simultaneously deliver the NO and the antibiotic, instead of 
individually, reducing the need for intravenously or orally delivered systemic antibiotics 
(Figure 4.2a). Kruszewski and coworkers immobilized vancomycin and gentamicin 
through amide bond formation, but a different orthogonal chemistry would be required to 
maintain the RSNO attachment developed here.10 This can be done through the use of 
different organic acid thin films containing different tail groups. The nanoparticles could 
also be dual functionalized to deliver NO and an antibiotic through the o/w emulsion 
synthesis technique. Here, an antibiotic could be encapsulated within the PLGA core of 
the nanoparticle, and then surface functionalized to release NO (Figure 4.3).25  
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Figure 4.3: Antibiotic encapsulation within the PLGA core of PLGA/PVA nanoparticles, 
with NO immobilized on the nanoparticle surface.  
 
In potential applications of NO delivery to the lungs, the nanoparticle surface 
could be functionalized with a NO and a mucolytic agent such as dithiothreitol (DTT) or 
N-acetylcysteine (NAC) (Figure 4.2).26, 27 DTT and NAC are commonly prescribed for 
individuals with CF, as it promotes the detachment of the thick mucus within a CF 
patient’s airway. Nanoparticle delivery to the CF lung could be complicated by this 
mucus layer in the airway, where the particles could be trapped within the airway and not 
disperse to the bacterial biofilms in the lower airway.  
Osseointegration of the NO releasing Ti-6Al-4V could be improved through dual 
functionalization with NO and a cell adhesion peptide (Figure 4.2c). Palchesko and co-
workers observed that osteoblast adhesion was improved upon attachment of the cell 
adhesion peptide lysine-arginine-serine-arginine (KRSR) to a calcium aluminate bone 
scaffold.12 Additionally, arginine-glycine-aspartic acid (RGD) was immobilized to the 
surface of Ti-6Al-4V metal oxide to enhance osteoblast attachment and spreading.28 
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Developing an implant material that contains a cell adhesion peptide and NO would 
promote osseointegration while preventing bacterial adhesion to the metal oxide implant 
surface.9   
 
4.4 Project Impact 
Due to increased incidences of antibiotic resistance, alternative antimicrobial 
compounds are required to ensure the long-term effective treatment for bacterial 
infections.29 An antibiotic alternative, NO, is an effective antimicrobial compound 
against both gram-positive and gram-negative bacterial species, and has been released 
through a variety of polymeric,30-34 silicate,1, 35-38 and metallic39-41 biomaterials. 
Unfortunately, most of these developed biomaterials utilize potentially carcinogenic 
NONOate NO donors instead of RSNO NO donors naturally produced by the human 
body. The development of a drug delivery vehicle or biomaterial capable of delivering 
naturally derived NO donors directly to the site of infection would significantly reduce 
the amount of systemic antibiotic usage, limiting the possibility of antibiotic resistance.9  
Here, a PLGA/PVA nanoparticle drug delivery vehicle and an implant 
biomaterial, Ti-6Al-4V, were modified at the surface to release amounts of NO that were 
bacteriostatic against E. coli and S. epidermidis planktonic cultures, while simultaneously 
increasing the effectiveness of traditionally prescribed antibiotics. These materials could 
reduce the usage of systemic antibiotics, as the antimicrobial delivery of NO is delivered 
directly to the site of infection. Unlike antibiotics, there has been limited observed gram-
positive and gram-negative bacterial resistance to exogenously delivered NO, likely due 
to the multiple mechanisms of NO bacterial toxicity.42  
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